Institutes,Name,Phase,Vaccine,Platform,N,Age (years),N doses,Rand.,Design,Location,Start date,Primary completion date,Trial number,Link,Status,Heterologous prime boost,Pregnancy,Children,Variant of concern,Multiple,Published,Paper
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),500000,≥18 (healthcare workers),1,No,Open-label,South Africa,18/02/2021,31/03/2022,NCT04838795,https://clinicaltrials.gov/ct2/show/NCT04838795,Recruiting,0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,121000,≥18,2,No,Open-label,China,05/06/2021,05/10/2021,NCT04911790,https://clinicaltrials.gov/ct2/show/NCT04911790,Recruiting,0,0,0,0,0,no,NA
Center for Genetic Engineering/and Biotechnology (peptide #1),CIGB-66/Abdala,Phase III,CIGB CIGB-66/Abdala,Protein subunit,48000,19–80,3,Yes,Double-blind,Cuba,22/03/2021,31/07/2021,IG/CIGB-66I/CVD19/2103,https://rpcec.sld.cu/en/trials/RPCEC00000359-En,Pending,0,0,0,0,0,no,NA
Beijing Institute of Biological Products/Wuhan Institute of Biological Products/Sinopharm,WIBP/BIBP vaccines,Phase III,WIBP/BIBP vaccines,Inactivated,45000,≥18,2,Yes,Double-blind,"Bahrain, Jordan, Egypt, UAE",16/07/2020,16/06/2021,NCT04510207,https://clinicaltrials.gov/ct2/show/NCT04510207,Recruiting,0,0,0,0,1,yes,"<a href=""https://jamanetwork.com/journals/jama/fullarticle/2780562"" style=""color:#006d2c"" target=""_blank"">Al Kaabi; JAMA 2021</a>"
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),44325,≥18,1,Yes,Double-blind,"USA, Argentina, Brazil, others",07/09/2020,22/01/2021,NCT04505722,https://clinicaltrials.gov/ct2/show/NCT04505722,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2101544"" style=""color:#006d2c"" target=""_blank"">Sadoff; NEJM 2021b</a>"
Instituto Finlay de Vacunas (peptide #2),Soberana 2,Phase III,Instituto Finlay de Vacunas Soberana 2,Protein subunit,44010,19–80,2 or 3,Yes,Double-blind,Cuba,05/03/2021,07/11/2021,IFV/COR/09,https://rpcec.sld.cu/en/trials/RPCEC00000354-En,Pending,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b1/b2/b2SA),Phase II/III,BioNTech BNT162 (b1/b2/b2SA),RNA,43998,≥12,2 +/- boost,Yes,"Observer-blind, dose-ranging","USA, Argentina, Brazil, others",29/04/2020,02/05/2023,NCT04368728,https://clinicaltrials.gov/ct2/show/NCT04368728,Recruiting,0,0,1,1,0,yes,"<a href=""https://www.nature.com/articles/s41586-020-2639-4"" style=""color:#006d2c"" target=""_blank"">Mulligan; Nature 2020</a><br><a href=""https://www.nature.com/articles/s41586-020-2814-7"" style=""color:#006d2c"" target=""_blank"">Sahin; Nature 2020</a><br><a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2027906"" style=""color:#006d2c"" target=""_blank"">Walsh; NEJM 2020</a><br><a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2034577"" style=""color:#006d2c"" target=""_blank"">Polack; NEJM 2020</a><br><a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2107456"" style=""color:#006d2c"" target=""_blank"">Frenck Jr; NEJM 2021</a><br><a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2110345"" style=""color:#006d2c"" target=""_blank"">Thomas; NEJM 2021</a>"
Razi Vaccine and Serum/Research Institute,Razi Cov Pars,Phase III,Razi Cov Pars,Protein subunit,41128,≥18,2,Yes,Double-blind,Iran,01/09/2021,,IRCT20210206050259N3,https://www.irct.ir/trial/58143,Recruiting,0,0,0,0,0,no,NA
Erciyes University (inactivated)/Sinovac,TURKOVAC/CoronaVac,Phase III,Erciyes TURKOVAC,Inactivated,40800,18–55,2,Yes,Observer-blind,Turkey,21/06/2021,21/01/2022,NCT04942405,https://clinicaltrials.gov/ct2/show/NCT04942405,Recruiting,0,0,0,0,1,no,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase III,Cansino Ad5-nCoV,Vector (non-replicating),40000,≥18,1,Yes,Double-blind,"Argentina, Chile, Mexico, others",15/09/2020,30/12/2021,NCT04526990,https://clinicaltrials.gov/ct2/show/NCT04526990,Recruiting,0,0,0,0,0,no,NA
"West China Hospital,/Sichuan University",Protein subunit vaccine,Phase III,West China Hospital protein subunit vaccine,Protein subunit,40000,≥18,3,Yes,Double-blind,"Indonesia, Kenya, Mexico, Philippines",15/06/2021,28/02/2022,NCT04904471,https://clinicaltrials.gov/ct2/show/NCT04904471,Enrolling by invitation,0,0,0,0,0,no,NA
CureVac,CVnCoV,Phase II/III,CureVac CVnCoV,RNA,39693,≥18,2,Yes,Observer-blind,"Argentina, Belgium, Colombia, others",14/12/2020,16/04/2021,NCT04652102,https://clinicaltrials.gov/ct2/show/NCT04652102,"Active, not recruiting",0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase III,Moderna mRNA-1273,RNA,37500,18–29,2,Yes,"Open-label, cross-over",USA,24/03/2021,22/12/2021,NCT04811664,https://clinicaltrials.gov/ct2/show/NCT04811664,Recruiting,0,0,0,0,0,no,NA
"Institute of Medical Biology,/Chinese Academy of Medical Sciences",Inactivated vaccine,Phase III,CAMS vaccine,Inactivated,34020,≥18,2,Yes,Double-blind,"Brazil, Malaysia",28/01/2021,30/09/2021,NCT04659239,https://clinicaltrials.gov/ct2/show/NCT04659239,Enrolling by invitation,0,0,0,0,0,no,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),33758,≥18,2,Yes,Double-blind,Russia,07/09/2020,01/05/2021,NCT04530396,https://clinicaltrials.gov/ct2/show/NCT04530396,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext"" style=""color:#006d2c"" target=""_blank"">Logunov; Lancet 2021</a>"
Novavax,NVX-CoV2373,Phase III,Novavax NVX-CoV2373,Protein subunit,33000,≥12,2,Yes,Observer-blind,"USA, Mexico, Puerto Rico",27/12/2020,30/06/2023,NCT04611802,https://clinicaltrials.gov/ct2/show/NCT04611802,"Active, not recruiting",0,0,1,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.10.05.21264567v1"" style=""color:#006d2c"" target=""_blank"">Dunkle; medRxiv 2021</a>"
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,33000,3–17,2,No,Open-label,China,24/07/2021,25/02/2022,NCT04992208,https://clinicaltrials.gov/ct2/show/NCT04992208,Recruiting,0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford ChAdOx1-S,Vector (non-replicating),32459,≥18,2,Yes,Double-blind,"USA, Argentina, Chile, others",28/08/2020,05/03/2021,NCT04516746,https://clinicaltrials.gov/ct2/show/NCT04516746,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2105290"" style=""color:#006d2c"" target=""_blank"">Falsey; NEJM 2021</a>"
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),31836,≥18,2,Yes,Double-blind,"USA, Belgium, Brazil, others",16/11/2020,10/05/2022,NCT04614948,https://clinicaltrials.gov/ct2/show/NCT04614948,"Active, not recruiting",0,0,0,0,0,no,NA
Medicago Inc,CoVLP,Phase II/III,Medicago CoVLP,Virus-like particle,30918,≥18,2,Yes,Observer-blind,"USA, Argentina, Brazil, others",19/11/2020,31/12/2021,NCT04636697,https://clinicaltrials.gov/ct2/show/NCT04636697,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.05.14.21257248v1"" style=""color:#006d2c"" target=""_blank"">Gobeil; medRxiv 2021</a>"
Moderna/NIAID,mRNA-1273,Phase III,Moderna mRNA-1273,RNA,30420,≥18,2,Yes,Observer-blind,USA,27/07/2020,27/10/2022,NCT04470427,https://clinicaltrials.gov/ct2/show/NCT04470427,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2035389"" style=""color:#006d2c"" target=""_blank"">Baden; NEJM 2020</a><br><a href=""https://www.medrxiv.org/content/10.1101/2021.09.17.21263624v1"" style=""color:#006d2c"" target=""_blank"">Baden; medRxiv 2021</a><br><a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2113017"" style=""color:#006d2c"" target=""_blank"">El Sahly; NEJM 2021</a><br><a href=""https://www.medrxiv.org/content/10.1101/2021.09.28.21264252v1"" target=""_blank"">Pajon; medRxiv 2021</a>"
University of Oxford/AstraZeneca,ChAdOx1-S (0.5 dose),Phase II/III,Oxford ChAdOx1-S (0.5 dose),Vector (non-replicating),29637,18–49,2,No,Open-label,Brazil,01/06/2021,01/06/2022,NCT05059106,https://clinicaltrials.gov/ct2/show/NCT05059106,Recruiting,0,0,0,0,0,no,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase III,AZLB ZF2001,Protein subunit,29000,≥18,Not stated,Yes,Double-blind,"China, Ecuador, Indonesia, others",16/12/2020,30/04/2022,NCT04646590,https://clinicaltrials.gov/ct2/show/NCT04646590,Recruiting,0,0,0,0,0,no,NA
Zydus Cadila Healthcare Limited (DNA),ZyCoV-D,Phase III,Zydus Cadila ZyCoV-D,DNA,28216,≥12,3,Yes,Double-blind,India,20/01/2021,20/09/2022,CTRI/2021/01/030416,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=51254&EncHid=&userName=ZyCoV-D,Recruiting,0,0,1,0,0,no,NA
Shenzhen Kangtai Biological Products Co Ltd,KCONVAC,Phase III,Shenzhen Kangtai KCONVAC,Inactivated,28000,≥18,2,Yes,Double-blind,Pending,01/05/2021,30/11/2021,NCT04852705,https://clinicaltrials.gov/ct2/show/NCT04852705,Not yet recruiting,0,0,0,0,0,no,NA
Walvax Biotech/PLA Academy of Military Sciences/Suzhou Abogen Biosciences,ARCoV,Phase III,Walvax ARCoV,RNA,28000,≥18,2,Yes,Double-blind,Pending,28/05/2021,30/10/2021,NCT04847102,https://clinicaltrials.gov/ct2/show/NCT04847102,Not yet recruiting,0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,27711,≥18,2,Yes,Stepped-wedge clusters,Brazil,07/02/2021,31/05/2021,NCT04747821,https://clinicaltrials.gov/ct2/show/NCT04747821,"Active, not recruiting",0,0,0,0,0,no,NA
Bharat Biotech/ICMR/National Institute of Virology,Covaxin,Phase III,Bharat Covaxin,Inactivated,25800,≥18,2,Yes,Double-blind,India,16/11/2020,08/01/2021,NCT04641481,https://clinicaltrials.gov/ct2/show/NCT04641481,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1"" style=""color:#006d2c"" target=""_blank"">Ella; medRxiv 2021</a>"
Guangdong Provincial CDC/Gaozhou CDC/Livson Pharmaceutical Group Inc,V-01,Phase III,Guangdong/Gaozhou V-01,Protein subunit,22500,≥18,2,Yes,Double-blind,Philippines,25/08/2021,02/03/2023,NCT05096845,https://clinicaltrials.gov/ct2/show/NCT05096845,Recruiting,0,0,0,0,0,no,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II/III,Clover SCB-2019,Protein subunit,22000,≥18,2,Yes,Double-blind,"Belgium, Brazil, Colombia, others",01/03/2021,31/07/2022,NCT04672395,https://clinicaltrials.gov/ct2/show/NCT04672395,Not yet recruiting,0,0,0,0,0,no,NA
Sanofi Pasteur/GSK,CoV2 preS dTM,Phase III,Sanofi/GSK CoV2 preS dTM,Protein subunit,21046,≥18,2,Yes,Double-blind,"USA, Colombia, Ghana, others",26/05/2021,27/01/2023,NCT04904549,https://clinicaltrials.gov/ct2/show/NCT04904549,Recruiting,0,0,0,0,0,no,NA
Arcturus/Vinbiocare,ARCT-154,Phase I/II/III,Arcturus ARCT-154,RNA,21000,≥18,2,Yes,Observer-blind,Vietnam,15/08/2021,28/02/2023,NCT05012943,https://clinicaltrials.gov/ct2/show/NCT05012943,Recruiting,0,0,0,0,0,no,NA
Jiangsu Rec-Biotechnology Co Ltd,ReCOV,Phase II/III,Jiangsu ReCOV,Protein subunit,20301,18–80,2,Yes,Double-blind,Pending,31/12/2021,31/12/2022,NCT05084989,https://clinicaltrials.gov/ct2/show/NCT05084989,Not yet recruiting,0,0,0,0,0,no,NA
Shifa Pharmed,COVIran,Phase II/III,Shifa Pharmed COVIran,Inactivated,20280,18–75,2,Yes,Double-blind,Iran,14/03/2021,,IRCT20201202049567N3,https://en.irct.ir/trial/54881,Recruiting,0,0,0,0,0,no,NA
Israel Institute for Biological Research/Weizmann Institute of Science,rVSV-SARS-CoV-2-S/IIBR-100,Phase II/III,IIBR rVSV-SARS-CoV-2-S,Vector (replicating),20000,18–90,2,Yes,Double-blind,Pending,30/09/2021,31/12/2021,NCT04990466,https://clinicaltrials.gov/ct2/show/NCT04990466,Not yet recruiting,0,0,0,0,0,no,NA
Vaxine Pty/Medytox/CinnaGen Co,SpikoGen,Phase III,Vaxine SpikoGen,Protein subunit,16876,18–50,2,Yes,Double-blind,Iran,07/08/2021,01/03/2022,NCT05005559,https://clinicaltrials.gov/ct2/show/NCT05005559,"Active, not recruiting",0,0,0,0,0,no,NA
Novavax,NVX-CoV2373,Phase III,Novavax NVX-CoV2373,Protein subunit,15000,18–84,2,Yes,Observer-blind,UK,28/11/2020,14/01/2022,NCT04583995,https://clinicaltrials.gov/ct2/show/NCT04583995,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2107659"" style=""color:#006d2c"" target=""_blank"">Heath; NEJM 2021</a><br><a href=""https://www.medrxiv.org/content/10.1101/2021.06.09.21258556v1"" style=""color:#006d2c"" target=""_blank"">Toback; medRxiv 2021</a>"
Genexine Consortium,GX-19N,Phase II/III,Genexine GX-19N,DNA,14000,≥18,2,Yes,Double-blind,Pending,01/10/2021,31/10/2022,NCT05067946,https://clinicaltrials.gov/ct2/show/NCT05067946,Not yet recruiting,0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,14000,0.5–17,2,Yes,Double-blind,Chile,10/09/2021,25/11/2021,NCT04992260,https://clinicaltrials.gov/ct2/show/NCT04992260,Recruiting,0,0,1,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase II/III,Moderna mRNA-1273,RNA,13275,0.5–11,2,Partial,"Open-label (part 1), observer-blind (part 2), dose-ranging",USA,15/03/2021,12/06/2023,NCT04796896,https://clinicaltrials.gov/ct2/show/NCT04796896,Recruiting,0,0,1,0,0,no,NA
Nanogen Biopharmaceutical,Nanocovax,Phase III,Nanogen Nanocovax,Protein subunit,13000,≥18,2,Yes,Double-blind,Vietnam,07/06/2021,07/07/2022,NCT04922788,https://clinicaltrials.gov/ct2/show/NCT04922788,Recruiting,0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,13000,18–59,2,Yes,Double-blind,Turkey,14/09/2020,15/02/2021,NCT04582344,https://clinicaltrials.gov/ct2/show/NCT04582344,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01429-X/fulltext"" style=""color:#006d2c"" target=""_blank"">Tanriover; Lancet 2021</a>"
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,12688,≥18,2,Yes,Double-blind,Brazil,21/07/2020,17/12/2020,NCT04456595,https://clinicaltrials.gov/ct2/show/NCT04456595,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3822780"" style=""color:#006d2c"" target=""_blank"">Palacios; Lancet preprint 2021</a>"
Sinocelltech Ltd,SCTV01C,Phase I/II/III,Sinocelltech SCTV01C,Protein subunit,12420,≥18,1,Yes,Double-blind,Pending,30/10/2021,01/05/2022,NCT05043311,https://clinicaltrials.gov/ct2/show/NCT05043311,Not yet recruiting,0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase II/III,Oxford ChAdOx1-S,Vector (non-replicating),12390,≥18,1 or 2 +/- boost,Yes,"Single-blind, dose-ranging",UK,28/05/2020,31/12/2021,NCT04400838,https://clinicaltrials.gov/ct2/show/NCT04400838,"Active, not recruiting",0,0,1,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32466-1/fulltext"" style=""color:#006d2c"" target=""_blank"">Ramasamy; Lancet 2020</a><br><a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext"" style=""color:#006d2c"" target=""_blank"">Voysey; Lancet 2020</a><br><a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/"" style=""color:#006d2c"" target=""_blank"">Voysey; Lancet 2021</a><br><a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0/fulltext"" style=""color:#006d2c"" target=""_blank"">Emary; Lancet 2021</a><br><a href=""https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00103-X/fulltext"" style=""color:#006d2c"" target=""_blank"">Frater; Lancet HIV 2021</a><br><a href=""https://www.medrxiv.org/content/10.1101/2021.06.17.21259027v1"" style=""color:#006d2c"" target=""_blank"">Swanson II; medRxiv 2021</a><br><a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01699-8/fulltext"" style=""color:#006d2c"" target=""_blank"">Flaxman; Lancet 2021</a><br></a><br><a href=""https://www.medrxiv.org/content/10.1101/2021.09.28.21264207v1"" style=""color:#006d2c"" target=""_blank"">Ogbe; medRxiv 2021</a>"
Beijing Institute of Biological Products/Wuhan Institute of Biological Products/Sinopharm,WIBP/BIBP vaccines,Phase III,WIBP/BIBP vaccines,Inactivated,12000,≥18,2,Yes,Double-blind,Peru,09/09/2020,19/02/2021,NCT04612972,https://clinicaltrials.gov/ct2/show/NCT04612972,"Active, not recruiting",0,0,0,0,1,no,NA
Guangdong Provincial CDC/Gaozhou CDC/Livson Pharmaceutical Group Inc,V-01,Phase III,Guangdong/Gaozhou V-01,Protein subunit,10722,≥18,1 (boost),Yes,Double-blind,Pakistan,31/10/2021,27/01/2023,NCT05096832,https://clinicaltrials.gov/ct2/show/NCT05096832,Not yet recruiting,0,0,0,0,0,no,NA
ReiThera/Leukocare/Univercells,GRAd-COV2,Phase II/III,ReiThera GRAd-COV2,Vector (non-replicating),10300,≥18,1 or 2,Yes,"Observer-blind, dose-ranging",Italy,15/03/2021,30/10/2021,NCT04791423,https://clinicaltrials.gov/ct2/show/NCT04791423,"Active, not recruiting",0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford ChAdOx1-S,Vector (non-replicating),10300,≥18,1 or 2,Yes,Single-blind,Brazil,02/06/2020,30/09/2021,NCT04536051,https://clinicaltrials.gov/ct2/show/NCT04536051,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext"" style=""color:#006d2c"" target=""_blank"">Voysey; Lancet 2020</a><br><a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/"" style=""color:#006d2c"" target=""_blank"">Voysey; Lancet 2021</a><br><a href=""https://www.nature.com/articles/s41467-021-25982-w"" style=""color:#006d2c"" target=""_blank"">Costa Clemens; Nat Comms 2021</a>"
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase III,BioNTech BNT162 (b2),RNA,10000,≥16,1 (boost),Yes,Double-blind,"USA, Brazil, Canada, South Africa",01/07/2021,17/07/2022,NCT04955626,https://clinicaltrials.gov/ct2/show/NCT04955626,Recruiting,0,0,1,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID/University of Oxford/AstraZeneca,BNT162/mRNA-1273/ChAdOx1-S,Phase IV,BNT162/mRNA-1273/ChAdOx1-S,RNA/Vector (non-replicating),10000,≥18,≥1,No,Open-label,Denmark,08/02/2021,31/12/2024,NCT04760132,https://clinicaltrials.gov/ct2/show/NCT04760132,Recruiting,0,0,0,0,1,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase III,BIBP BBIBP-CorV,Inactivated,8825,≥18,2 + boost,Yes,Observer-blind,Pending,01/10/2021,30/09/2024,NCT04984408,https://clinicaltrials.gov/ct2/show/NCT04984408,Not yet recruiting,0,0,0,0,0,no,NA
Sinocelltech Ltd,SCTV01C,Phase I/II/III,Sinocelltech SCTV01C,Protein subunit,8420,≥18,1,Yes,Double-blind,Pending,30/10/2021,01/05/2022,NCT05043285,https://clinicaltrials.gov/ct2/show/NCT05043285,Not yet recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase I/II/III,BioNTech BNT162 (b2),RNA,7922,0.5–30,2,No,"Open-label (phase I), observer-blind (phase II/III), dose-ranging","USA, Finland, Poland, Spain",24/03/2021,18/06/2024,NCT04816643,https://clinicaltrials.gov/ct2/show/NCT04816643,Recruiting,0,0,1,0,0,no,NA
Inovio Pharmaceuticals/International Vaccine Institute,INO-4800,Phase II/III,Inovio INO-4800,DNA,7517,≥18,2,Yes,"Double-blind, dose-ranging","USA, Brazil, Colombia, others",30/11/2020,31/01/2023,NCT04642638,https://clinicaltrials.gov/ct2/show/NCT04642638,Recruiting,0,0,0,0,0,no,NA
Erciyes University (inactivated)/Sinovac,TURKOVAC/CoronaVac,Phase III,TURKOVAC/CoronaVac,Inactivated,7400,18–59,1 (boost),No,Open-label,Turkey,08/10/2021,05/04/2022,NCT05077176,https://clinicaltrials.gov/ct2/show/NCT05077176,Recruiting,0,0,0,0,1,no,NA
Vaxxinity,UB-612,Phase II/III,Vaxxinity UB-612,Protein subunit,7320,≥18,2,Yes,Double-blind,Pending,01/02/2021,22/03/2023,NCT04683224,https://clinicaltrials.gov/ct2/show/NCT04683224,Not yet recruiting,0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,6233,18–49,2,No,Open-label,Brazil,18/03/2021,05/07/2021,NCT04789356,https://clinicaltrials.gov/ct2/show/NCT04789356,"Active, not recruiting",0,0,0,0,0,no,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),6000,≥18,1,Yes,Double-blind,Russia,19/02/2021,31/12/2021,NCT04741061,https://clinicaltrials.gov/ct2/show/NCT04741061,Recruiting,0,0,0,0,0,no,NA
Sanofi Pasteur/GSK,CoV2 preS dTM (D614 +/- B.1.351),Phase II/III,Sanofi/GSK CoV2 preS dTM,Protein subunit,5414,≥18,1 (boost) or 2,Yes,"Open-label, observer-blind, or double-blind depending on phase","USA, Australia, France, others",24/02/2021,11/01/2023,NCT04762680,https://clinicaltrials.gov/ct2/show/NCT04762680,Recruiting,0,0,0,1,0,no,NA
Instituto Butantan/Dynavax/PATH,"NDV-HXP-S (WT, P.1, B.1.351)",Phase I/II,"Butantan NDV-HXP-S (WT, P.1, B.1.351)",Inactivated,5394,≥18,2,Yes,Double-blind,Brazil,09/07/2021,30/04/2023,NCT04993209,https://clinicaltrials.gov/ct2/show/NCT04993209,Recruiting,0,0,0,1,0,no,NA
Valneva/Dynavax/University of Oxford/AstraZeneca,VLA2001/ChAdOx1-S,Phase III,VLA2001/ChAdOx1-S,Inactivated/Vector (non-replicating),4679,≥12,2,Yes,Observer-blind,UK,26/04/2021,28/02/2022,NCT04864561,https://clinicaltrials.gov/ct2/show/NCT04864561,Recruiting,0,0,1,0,1,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase IV,BIBP BBIBP-CorV,Inactivated,4400,≥3,2 or 3,Yes,Open-label,China,29/04/2021,31/03/2022,NCT04863638,https://clinicaltrials.gov/ct2/show/NCT04863638,Recruiting,0,0,1,0,0,no,NA
Novavax,NVX-CoV2373,Phase II,Novavax NVX-CoV2373,Protein subunit,4400,18–84,2,Yes,Observer-blind,South Africa,17/08/2020,30/11/2021,NCT04533399,https://clinicaltrials.gov/ct2/show/NCT04533399,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2103055"" style=""color:#006d2c"" target=""_blank"">Shinde; NEJM 2021</a>"
University of Oxford/AstraZeneca/Beijing Institute of Biological Products/Sinopharm,ChAdOx1-S/BBIBP-CorV,Phase II/III,ChAdOx1-S/BBIBP-CorV,Vector (non-replicating)/Inactivated,4000,≥18,2,No,Open-label,Egypt,23/02/2021,01/10/2021,NCT04885764,https://clinicaltrials.gov/ct2/show/NCT04885764,Recruiting,0,0,0,0,1,no,NA
SK Biosciences (peptide #1),GBP510,Phase III,SK Biosciences GBP510,Protein subunit,3990,≥18,2,Yes,Observer-blind,"Republic of Korea, New Zealand, Philippines, others",30/08/2021,31/03/2022,NCT05007951,https://clinicaltrials.gov/ct2/show/NCT05007951,Recruiting,0,0,0,0,0,no,NA
Medigen Vaccine Biologics Corporation/NIAID/Dynavax,MVC-COV1901,Phase II,Medigen MVC-COV1901,Protein subunit,3854,≥20,2,Yes,Double-blind,"Taiwan, Vietnam",30/12/2020,02/06/2021,NCT04695652,https://clinicaltrials.gov/ct2/show/NCT04695652,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00402-1/fulltext"" style=""color:#006d2c"" target=""_blank"">Hsieh; Lancet Resp Med 2021</a>"
Vaxxinity,UB-612,Phase II,Vaxxinity UB-612,Protein subunit,3850,12–85,2,Yes,Observer-blind,Taiwan,30/01/2021,27/06/2021,NCT04773067,https://clinicaltrials.gov/ct2/show/NCT04773067,Recruiting,0,0,1,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase II/III,Moderna mRNA-1273,RNA,3732,12–17,2,Yes,Observer-blind,USA,09/12/2020,30/06/2022,NCT04649151,https://clinicaltrials.gov/ct2/show/NCT04649151,"Active, not recruiting",0,0,1,0,0,yes,"<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2109522"" style=""color:#006d2c"" target=""_blank"">Ali; NEJM 2021</a>"
Moderna/NIAID,mRNA-1273.211,Phase II/III,Moderna mRNA-1273.211,RNA,3620,≥18,1 (boost),No,"Open-label, dose-ranging",USA,28/05/2021,16/06/2022,NCT04927065,https://clinicaltrials.gov/ct2/show/NCT04927065,Recruiting,0,0,0,1,0,no,NA
National Vaccine and Serum Institute/Lanzhou Institute of Biological Products Co Ltd,NVSI-06-08,Phase I/II,NVSI-06-08,Protein subunit,3580,≥3,3,Yes,"Double-blind, dose-ranging",China,25/04/2021,25/10/2022,NCT04869592,https://clinicaltrials.gov/ct2/show/NCT04869592,Recruiting,0,0,1,0,0,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase III,BIBP BBIBP-CorV,Inactivated,3000,18–85,2,Yes,Double-blind,Argentina,16/09/2020,01/12/2021,NCT04560881,https://clinicaltrials.gov/ct2/show/NCT04560881,"Active, not recruiting",0,0,0,0,0,no,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase II/III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),3000,12–17,2,No,"Open-label, dose-ranging",Russia,05/07/2021,06/11/2022,NCT04954092,https://clinicaltrials.gov/ct2/show/NCT04954092,Recruiting,0,0,1,0,0,no,NA
"Heterologous - RNA, Vector",BNT162/ChAdOx1-S,Phase II,BNT162/ChAdOx1-S,Heterologous,3000,18–65,2,Yes,Single-blind,Austria,10/05/2021,30/11/2021,NCT04907331,https://clinicaltrials.gov/ct2/show/NCT04907331,Recruiting,1,0,0,0,1,no,NA
Research Institute for/Biological Safety Problems (inactivated),QazCovid-in,Phase III,RIBSP QazCovid-in,Inactivated,3000,≥18,2,Yes,Single-blind,Kazakhstan,25/12/2020,26/04/2021,NCT04691908,https://clinicaltrials.gov/ct2/show/NCT04691908,Completed,0,0,0,0,0,no,NA
Vector Institute (peptide),EpiVacCorona,Phase III,Vector Institute EpiVacCorona,Protein subunit,3000,≥18,2,Yes,Double-blind,Russia,18/11/2020,31/08/2021,NCT04780035,https://clinicaltrials.gov/ct2/show/NCT04780035,"Active, not recruiting",0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S (AZD2816),Phase II/III,Oxford ChAdOx1-S (AZD2816),Vector (non-replicating),2849,≥18,1 (boost) or 2,Yes,Double-blind,"Brazil, Poland, South Africa, UK",27/06/2021,08/10/2021,NCT04973449,https://clinicaltrials.gov/ct2/show/NCT04973449,Recruiting,0,0,0,1,0,no,NA
"Heterologous - Protein subunit, RNA, Vector",BNT162/CVnCoV/mRNA-1273/NVX-CoV2373/ChAdOx1-S/VLA2001,Phase II,BNT162/CVnCoV/mRNA-1273/NVX-CoV2373/ChAdOx1-S/VLA2001,Heterologous,2664,≥30,2 + boost,Yes,Single-blind,UK,01/06/2021,01/08/2022,ISRCTN73765130,https://www.isrctn.com/ISRCTN73765130,Not yet recruiting,0,0,0,1,1,no,NA
CureVac,CVnCoV,Phase III,CureVac CVnCoV,RNA,2360,≥18,2,Yes,Observer-blind,Germany,23/12/2020,30/06/2022,NCT04674189,https://clinicaltrials.gov/ct2/show/NCT04674189,"Active, not recruiting",0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,2300,≥18,2,Yes,Open-label,Chile,27/11/2020,31/01/2022,NCT04651790,https://clinicaltrials.gov/ct2/show/NCT04651790,Recruiting,0,0,0,0,0,yes,"<a href=""https://pubmed.ncbi.nlm.nih.gov/34537835/"" style=""color:#006d2c"" target=""_blank"">Bueno; Clin Infect Dis 2021</a>"
University of Oxford/AstraZeneca,ChAdOx1-S,Not specified,Oxford ChAdOx1-S,Vector (non-replicating),2200,≥18 (cirrhosis),2,No,Open-label,India,19/03/2021,19/03/2022,NCT04794946,https://clinicaltrials.gov/ct2/show/NCT04794946,Recruiting,0,0,0,0,0,no,NA
Biological E Ltd,BECOV,Phase III,Biological E Ltd BECOV,Protein subunit,2140,18–80,2,Yes,Single-blind,India,03/09/2021,03/07/2022,CTRI/2021/08/036074,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=59772,Recruiting,0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase I/II,Oxford ChAdOx1-S,Vector (non-replicating),2130,18–65,1 or 2,Yes,Double-blind,South Africa,24/06/2020,31/12/2020,NCT04444674,https://clinicaltrials.gov/ct2/show/NCT04444674,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext"" style=""color:#006d2c"" target=""_blank"">Voysey; Lancet 2020</a><br><a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/"" style=""color:#006d2c"" target=""_blank"">Voysey; Lancet 2021</a><br><a href=""https://www.nejm.org/doi/10.1056/NEJMoa2102214"" style=""color:#006d2c"" target=""_blank"">Madhi; NEJM 2021</a><br><a href=""https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00157-0/fulltext"" target=""_blank"">Madhi; Lancet HIV 2021</a>"
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase I/II,BIBP BBIBP-CorV,Inactivated,2128,≥3,Up to 3,Yes,"Double-blind, dose-ranging",China,28/04/2020,28/11/2021,ChiCTR2000032459,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000032459,Recruiting,0,0,1,0,0,yes,"<a href=""https://www.sciencedirect.com/science/article/pii/S1473309920308318?via%3Dihub"" style=""color:#006d2c"" target=""_blank"">Xia; Lancet Infect Dis 2020</a><br><a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00462-X/fulltext"" style=""color:#006d2c"" target=""_blank"">Xia; Lancet Infect Dis 2021</a>"
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,2067,≥18 (autoimmune),2,No,Open-label,Brazil,09/02/2021,30/12/2021,NCT04754698,https://clinicaltrials.gov/ct2/show/NCT04754698,"Active, not recruiting",0,0,0,0,0,no,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Not specified,Cansino Ad5-nCoV,Vector (non-replicating),2016,6–59,1,Yes,"Observer-blind, dose-ranging",China,03/06/2021,31/05/2022,NCT04916886,https://clinicaltrials.gov/ct2/show/NCT04916886,Recruiting,0,0,1,0,0,no,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),2000,≥18,2,Yes,Double-blind,Venezuala,01/11/2020,31/10/2021,NCT04642339,https://clinicaltrials.gov/ct2/show/NCT04642339,Not yet recruiting,0,0,0,0,0,no,NA
"Heterologous - Inactivated, Protein subunit",BBIBP-CorV/NVSI-06-08,Phase III,BBIBP-CorV/NVSI-06-08,Heterologous,1848,≥18,1 (boost),Yes,"Double-blind, dose-ranging",UAE,14/10/2021,31/12/2023,NCT05069129,https://clinicaltrials.gov/ct2/show/NCT05069129,Recruiting,1,0,0,0,1,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase IV,BIBP BBIBP-CorV,Inactivated,1800,≥3,2,Yes,Open-label,UAE,06/06/2021,06/02/2022,NCT04917523,https://clinicaltrials.gov/ct2/show/NCT04917523,Not yet recruiting,0,0,1,0,0,no,NA
"Heterologous - Inactivated, Protein subunit",CAMS vaccine/NVSI-06-08,Phase III,CAMS vaccine/NVSI-06-08,Heterologous,1800,≥18,1 (boost),Yes,Double-blind,UAE,12/09/2021,30/11/2023,NCT05033847,https://clinicaltrials.gov/ct2/show/NCT05033847,Recruiting,1,0,0,0,1,no,NA
"Heterologous - Inactivated, Vector",BNT162/Gam-COVID-Vac/mRNA-1273/ChAdOx1-S,Phase II,BNT162/Gam-COVID-Vac/mRNA-1273/ChAdOx1-S,Heterologous,1760,≥18,2,Yes,Open-label,Argentina,03/08/2021,30/09/2021,NCT04988048,https://clinicaltrials.gov/ct2/show/NCT04988048,Recruiting,1,0,0,0,1,no,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase III,AZLB ZF2001,Protein subunit,1680,18–59,3,Yes,Double-blind,China,09/09/2021,30/11/2021,NCT05091411,https://clinicaltrials.gov/ct2/show/NCT05091411,Recruiting,0,0,0,0,0,no,NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase III,Janssen Ad26.COV2.S,Vector (non-replicating),1680,≥18,1,Yes,Double-blind,"USA, Belgium, Poland, Spain",02/11/2021,06/01/2022,NCT05091307,https://clinicaltrials.gov/ct2/show/NCT05091307,Not yet recruiting,0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,1620,18–59,2,Yes,Observer-blind,Indonesia,10/08/2020,09/01/2021,NCT04508075,https://clinicaltrials.gov/ct2/show/NCT04508075,Completed,0,0,0,0,0,yes,"<a href=""https://www.sciencedirect.com/science/article/pii/S0264410X2101255X?via%3Dihub"" style=""color:#006d2c"" target=""_blank"">Fadlyana; Vaccine 2021</a>"
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase II/III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),1600,≥18,2,Yes,Double-blind,India,30/11/2020,30/08/2021,NCT04640233,https://clinicaltrials.gov/ct2/show/NCT04640233,"Active, not recruiting",0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase II/III,Oxford ChAdOx1-S,Vector (non-replicating),1600,≥18,2,Yes,Observer-blind,India,24/08/2020,24/03/2021,CTRI/2020/08/027170,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=46186&EncHid=&userName=covid-19%20vaccine,Completed,0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273 +/- HZ/IVV,Phase III,Moderna mRNA-1273,RNA,1546,≥18,1 (boost),Yes,Open-label,USA,07/10/2021,29/03/2022,NCT05047770,https://clinicaltrials.gov/ct2/show/NCT05047770,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2/b2.B.1.351),Phase III,BioNTech BNT162 (b2/b2.B.1.351),RNA,1530,12–50,1 (boost) or 2,Yes,"Observer-blind, dose-ranging",USA,15/02/2021,22/07/2021,NCT04713553,https://clinicaltrials.gov/ct2/show/NCT04713553,Completed,0,0,1,1,0,no,NA
Wuhan Institute of Biological Products/Sinopharm,WIBP vaccine ,Phase IV,WIBP vaccine ,Inactivated,1440,≥60,2,No,Single-blind (outcomes assessor),China,01/10/2021,31/01/2022,NCT05065892,https://clinicaltrials.gov/ct2/show/NCT05065892,Not yet recruiting,0,0,0,0,0,no,NA
Wuhan Institute of Biological Products/Sinopharm,WIBP vaccine ,Phase IV,WIBP vaccine ,Inactivated,1440,≥60,1 (boost),No,Single-blind (outcomes assessor),China,01/11/2021,30/11/2022,NCT05104437,https://clinicaltrials.gov/ct2/show/NCT05104437,Not yet recruiting,0,0,0,0,0,no,NA
Wuhan Institute of Biological Products/Sinopharm,WIBP vaccine ,Phase IV,WIBP vaccine ,Inactivated,1440,≥60 (hypertension/diabetes),1 (boost),No,Single-blind (outcomes assessor),China,01/11/2021,30/11/2022,NCT05104437,https://clinicaltrials.gov/ct2/show/NCT05104437,Not yet recruiting,0,0,0,0,0,no,NA
Novavax,NVX-CoV2373,Phase I/II,Novavax NVX-CoV2373,Protein subunit,1419,18–84,"1, 2 or 3",Yes,"Observer-blind, dose-ranging","USA, Australia",25/05/2020,21/05/2022,NCT04368988,https://clinicaltrials.gov/ct2/show/NCT04368988,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2026920"" style=""color:#006d2c"" target=""_blank"">Keech; NEJM 2020</a><br><a href=""https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003769"" style=""color:#006d2c"" target=""_blank"">Formica; PLoS Medicine 2021</a>"
Wuhan Institute of Biological Products/Sinopharm,WIBP vaccine +/- PPV/IIV4,Phase IV,WIBP vaccine ,Inactivated,1404,≥18,2,Yes,Single-blind (outcomes assessor),China,06/05/2021,29/05/2021,NCT05079152,https://clinicaltrials.gov/ct2/show/NCT05079152,"Active, not recruiting",0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,1400,18–59,1 (boost),Yes,Open-label,China,19/06/2021,19/08/2021,NCT04962308,https://clinicaltrials.gov/ct2/show/NCT04962308,Recruiting,0,0,0,0,0,no,NA
"Heterologous - Inactivated, RNA, Vector",BNT162/CoronaVac/ChAdOx1-S,Phase II,BNT162/CoronaVac/ChAdOx1-S,Heterologous,1320,18–59,1 (boost),Yes,"Observer-blind, dose-ranging",Pending,01/09/2021,30/09/2022,NCT05049226,https://clinicaltrials.gov/ct2/show/NCT05049226,Not yet recruiting,1,0,0,0,1,no,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,1320,≥18,2,Yes,Double-blind,China,01/09/2021,01/05/2022,NCT04993365,https://clinicaltrials.gov/ct2/show/NCT04993365,Not yet recruiting,0,0,0,0,0,no,NA
Wuhan Institute of Biological Products/Sinopharm,WIBP vaccine ,Phase I/II,WIBP vaccine ,Inactivated,1264,≥6,Up to 3,Yes,"Double-blind, dose-ranging",China,11/04/2020,10/11/2021,ChiCTR2000031809,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000031809,Pending,0,0,1,0,0,yes,"<a href=""https://jamanetwork.com/journals/jama/fullarticle/2769612"" style=""color:#006d2c"" target=""_blank"">Xia; JAMA 2020</a><br><a href=""https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00290-X/fulltext"" style=""color:#006d2c"" target=""_blank"">Guo; EClinicalMedicine 2021</a>"
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2/B.1.1.7/B.617.2),Phase II,BioNTech BNT162 (b2/B.1.1.7/B.617.2),RNA,1245,18–85,1 (boost) or 2,No,Open-label,USA,25/08/2021,31/01/2022,NCT05004181,https://clinicaltrials.gov/ct2/show/NCT05004181,Recruiting,0,0,0,1,0,no,NA
"Heterologous - RNA, Vector",BNT162/mRNA-1273/ChAdOx1-S,Phase II,BNT162/mRNA-1273/ChAdOx1-S,Heterologous,1200,≥18,2,Yes,Double-blind,Canada,20/05/2021,31/03/2023,NCT04894435,https://clinicaltrials.gov/ct2/show/NCT04894435,Recruiting,1,0,0,0,1,no,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,1200,≥18,2,No,Open-label,Brazil,19/02/2021,30/09/2021,NCT04756830,https://clinicaltrials.gov/ct2/show/NCT04756830,"Active, not recruiting",0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,1200,≥18,1 (boost),Yes,"Double-blind, dose-ranging",China,01/11/2021,01/12/2021,NCT05079217,https://clinicaltrials.gov/ct2/show/NCT05079217,Not yet recruiting,0,0,0,0,0,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase IV,BIBP BBIBP-CorV,Inactivated,1133,≥18,2,Yes,Single-blind (outcomes assessor),China,10/03/2021,05/09/2021,NCT04790851,https://clinicaltrials.gov/ct2/show/NCT04790851,Completed,0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase I/II,Oxford ChAdOx1-S,Vector (non-replicating),1090,18–55,Up to 3,Yes,"Single-blind, dose-ranging",UK,23/04/2020,31/10/2021,NCT04324606,https://clinicaltrials.gov/ct2/show/NCT04324606,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext"" style=""color:#006d2c"" target=""_blank"">Folegatti; Lancet 2020</a><br><a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext"" style=""color:#006d2c"" target=""_blank"">Voysey; Lancet 2020</a><br><a href=""https://www.nature.com/articles/s41591-020-01194-5"" style=""color:#006d2c"" target=""_blank"">Ewer; Nature Med 2020 </a><br><a href=""https://www.nature.com/articles/s41591-020-01179-4"" style=""color:#006d2c"" target=""_blank"">Barrett; Nature Med 2020</a><br><a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00432-3/"" style=""color:#006d2c"" target=""_blank"">Voysey; Lancet 2021</a><br><a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01699-8/fulltext"" style=""color:#006d2c"" target=""_blank"">Flaxman; Lancet 2021</a>"
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase I/II,Janssen Ad26.COV2.S,Vector (non-replicating),1085,≥18,1 or 2 +/- boost,Yes,"Double-blind, dose-ranging","USA, Belgium",15/07/2020,03/12/2021,NCT04436276,https://clinicaltrials.gov/ct2/show/NCT04436276,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2034201"" style=""color:#006d2c"" target=""_blank"">Sadoff; NEJM 2021</a><br><a href=""https://jamanetwork.com/journals/jama/fullarticle/2777598"" style=""color:#006d2c"" target=""_blank"">Stephenson; JAMA 2021</a><br><a href=""https://www.nature.com/articles/s41586-021-03681-2"" style=""color:#006d2c"" target=""_blank"">Alter; Nature 2021</a><br><a href=""https://www.medrxiv.org/content/10.1101/2021.08.25.21262569v1"" style=""color:#006d2c"" target=""_blank"">Sadoff; medRxiv 2021</a>"
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,1080,26–45,2,Yes,Double-blind,China,11/05/2021,30/11/2021,NCT04894227,https://clinicaltrials.gov/ct2/show/NCT04894227,"Active, not recruiting",0,0,0,0,0,no,NA
Shanghai Zerun Biotechnology Co Ltd/Walvax Biotech,202-CoV,Phase II,Shanghai Zerun 202-CoV,Protein subunit,1056,≥18,2,Yes,"Double-blind, dose-ranging",China,31/07/2021,31/12/2021,NCT04990544,https://clinicaltrials.gov/ct2/show/NCT04990544,Recruiting,0,0,0,0,0,no,NA
Zydus Cadila Healthcare Limited (DNA),ZyCoV-D,Phase I/II,Zydus Cadila ZyCoV-D,DNA,1048,18–55,3,Yes,Double-blind,India,13/07/2020,13/07/2021,CTRI/2020/07/026352,http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45306&EncHid=&userName=Zydus,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.sciencedirect.com/user/identity/landing?code=TeB3rRacs3vLn7DGX5X_DBx_VviiI-P1PYwMd2b6&state=retryCounter%3D0%26csrfToken%3D2cd1753d-e869-4788-94c6-1148d79354cb%26idpPolicy%3Durn%253Acom%253Aelsevier%253Aidp%253Apolicy%253Aproduct%253Ainst_assoc%26returnUrl%3D%252Fscience%252Farticle%252Fpii%252FS258953702100300X%26prompt%3Dnone%26cid%3Darp-b8082805-5a24-46d2-9817-ebf94a76467a"" style=""color:#006d2c"" target=""_blank"">Momin; EClinicalMedicine 2021</a>"
Israel Institute for Biological Research/Weizmann Institute of Science,rVSV-SARS-CoV-2-S/IIBR-100,Phase I/II,IIBR rVSV-SARS-CoV-2-S,Vector (replicating),1040,18–85,1 or 2,Yes,"Double-blind, dose-ranging",Israel,28/10/2020,01/05/2021,NCT04608305,https://clinicaltrials.gov/ct2/show/NCT04608305,Recruiting,0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase III,Sinovac CoronaVac,Inactivated,1040,≥18,2,Yes,Double-blind,China,31/10/2020,28/11/2020,NCT04617483,https://clinicaltrials.gov/ct2/show/NCT04617483,Completed,0,0,0,0,0,no,NA
Medigen Vaccine Biologics Corporation/NIAID/Dynavax,MVC-COV1901,Phase III,MVC-COV1901,Protein subunit,1020,≥18,2,Yes,Double-blind,Pending,01/10/2021,28/02/2022,NCT05011526,https://clinicaltrials.gov/ct2/show/NCT05011526,Not yet recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Not specified,BioNTech BNT162 (b2),RNA,1000,≥18 (leukaemia),2,No,Open-label,Israel,01/02/2021,30/09/2021,NCT04862806,https://clinicaltrials.gov/ct2/show/NCT04862806,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase I,BioNTech BNT162 (b1/b2/b2SA),RNA,1000,≥18 (cancer),1 (boost),No,Open-label,USA,07/06/2021,01/09/2021,NCT04936997,https://clinicaltrials.gov/ct2/show/NCT04936997,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.nature.com/articles/s41591-021-01542-z"" style=""color:#006d2c"" target=""_blank"">Shroff; Nat Med 2021</a>"
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2) intradermal,Phase III,BioNTech BNT162 (b2) intradermal,RNA,1000,≥18,1 (boost),Yes,Single-blind,Pending,31/08/2021,31/08/2022,NCT05029245,https://clinicaltrials.gov/ct2/show/NCT05029245,Not yet recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID,BNT162/mRNA-1273,Phase IV,BNT162/mRNA-1273,RNA,1000,≥18 (immunocompromised),1 (boost),No,Open-label,Norway,29/06/2021,29/09/2023,EUCTR2021-003618-37-NO,https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003618-37/NO,Ongoing,0,0,0,0,1,no,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),1000,≥18,2,Yes,Double-blind,UAE,01/12/2020,31/08/2021,NCT04656613,https://clinicaltrials.gov/ct2/show/NCT04656613,Not yet recruiting,0,0,0,0,0,no,NA
Shenzhen Kangtai Biological Products Co Ltd,KCONVAC,Phase II,Shenzhen Kangtai KCONVAC,Inactivated,1000,≥18,2 or 3,Yes,"Double-blind, dose-confirmation",China,27/10/2020,30/06/2021,NCT04756323,https://clinicaltrials.gov/ct2/show/NCT04756323,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://journals.lww.com/cmj/Abstract/9000/Immunogenicity_and_safety_of_a_SARS_CoV_2.98627.aspx"" style=""color:#006d2c"" target=""_blank"">Pan; Chin Med J 2021</a>"
"West China Hospital,/Sichuan University",Protein subunit vaccine,Phase II,West China Hospital protein subunit vaccine,Protein subunit,960,18–85,2 or 3,Yes,Double-blind,China,17/11/2020,18/02/2021,NCT04640402,https://clinicaltrials.gov/ct2/show/NCT04640402,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.nature.com/articles/s41392-021-00692-3"" style=""color:#006d2c"" target=""_blank"">Meng; Signal Transduct Target Ther 2021</a>"
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase II,BioNTech BNT162 (b1/b2),RNA,950,18–85,2,Yes,Observer-blind,China,04/12/2020,31/12/2022,NCT04649021,https://clinicaltrials.gov/ct2/show/NCT04649021,"Active, not recruiting",0,0,0,0,0,no,NA
"Heterologous - RNA, Vector",Ad26.COV2.S/BNT162/mRNA-1273/mRNA-1273.211,Phase I/II,Ad26.COV2.S/BNT162/mRNA-1273/mRNA-1273.211,Heterologous,950,≥18,1 (boost),No,Open-label,USA,28/05/2021,01/12/2022,NCT04889209,https://clinicaltrials.gov/ct2/show/NCT04889209,Recruiting,1,0,0,1,1,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v2"" style=""color:#006d2c"" target=""_blank"">Atmar; medRxiv 2021</a>"
"Institute of Medical Biology,/Chinese Academy of Medical Sciences",Inactivated vaccine,Phase I/II,CAMS vaccine,Inactivated,942,18–59,2,Yes,"Double-blind, dose-ranging",China,15/05/2020,30/09/2020,NCT04412538,https://clinicaltrials.gov/ct2/show/NCT04412538,Recruiting,0,0,0,0,0,yes,"<a href=""https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1703/5962856"" style=""color:#006d2c"" target=""_blank"">Che; Clin Infect Dis 2020</a><br><a href=""https://www.sciencedirect.com/science/article/pii/S0264410X2100431X?via%3Dihub"" style=""color:#006d2c"" target=""_blank"">Pu; Vaccine 2021</a>"
Medicago Inc,CoVLP,Phase II,Medicago CoVLP,Virus-like particle,918,≥18,2,Yes,Observer-blind,USA,11/12/2020,31/12/2021,NCT04662697,https://clinicaltrials.gov/ct2/show/NCT04662697,Not yet recruiting,0,0,0,0,0,no,NA
Instituto Finlay de Vacunas (peptide #2),Soberana 2,Phase II,Instituto Finlay de Vacunas Soberana 2,Protein subunit,910,19–80,2,Yes,Double-blind,Cuba,21/12/2020,12/03/2021,IFV/COR/08,https://rpcec.sld.cu/en/trials/RPCEC00000347-En,Recruitment complete,0,0,0,0,0,no,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase II,AZLB ZF2001,Protein subunit,900,18–59,2 or 3,Yes,Double-blind,China,12/07/2020,15/09/2021,NCT04466085,https://clinicaltrials.gov/ct2/show/NCT04466085,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00127-4/fulltext"" style=""color:#006d2c"" target=""_blank"">Yang; Lancet Infect Dis 2021</a>"
BioNTech/Pfizer/Fosun Pharma/Sinovac/University of Oxford/AstraZeneca,BNT162/CoronaVac/ChAdOx1-S,Phase IV,BNT162/CoronaVac/ChAdOx1-S,RNA/Inactivated/Vector (non-replicating),900,≥18 (chronic liver disease),2,No,Open-label,Hong Kong,21/05/2021,31/12/2021,NCT04775069,https://clinicaltrials.gov/ct2/show/NCT04775069,Recruiting,0,0,0,0,1,no,NA
BioNTech/Pfizer/Fosun Pharma/Sinovac/University of Oxford/AstraZeneca,BNT162/CoronaVac/ChAdOx1-S,Phase III,BNT162/CoronaVac/ChAdOx1-S,RNA/Inactivated/Vector (non-replicating),900,≥11,2,No,Open-label,Hong Kong,08/05/2021,31/03/2025,NCT04800133,https://clinicaltrials.gov/ct2/show/NCT04800133,Recruiting,0,0,1,0,1,no,NA
Medicago Inc,CoVLP,Phase III,Medicago CoVLP,Virus-like particle,900,18–49,2,Yes,Observer-blind,Canada,22/11/2021,31/05/2022,NCT05040789,https://clinicaltrials.gov/ct2/show/NCT05040789,Not yet recruiting,0,0,0,0,0,no,NA
Valneva/Dynavax,VLA2001/VLA2101,Phase III,Valneva VLA2001/VLA2101,Inactivated,900,≥12,2,Yes,Observer-blind,New Zealand,09/08/2021,30/04/2022,NCT04956224,https://clinicaltrials.gov/ct2/show/NCT04956224,"Active, not recruiting",0,0,1,1,0,no,NA
Vaxart,VXA-CoV2-1.1-S,Phase II,Vaxart VXA-CoV2-1.1-S,Vector (non-replicating),896,18–75,2,Yes,"Double-blind, dose-ranging",USA,01/10/2021,31/03/2022,NCT05067933,https://clinicaltrials.gov/ct2/show/NCT05067933,Recruiting,0,0,0,0,0,no,NA
Guangdong Provincial CDC/Gaozhou CDC/Livson Pharmaceutical Group Inc,V-01,Phase II,Guangdong/Gaozhou V-01,Protein subunit,880,≥18,1 or 2,Yes,"Double-blind, dose-ranging",China,28/03/2021,30/07/2022,ChiCTR2100045107,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100045107,Pending,0,0,0,0,0,yes,"<a href=""https://journals.lww.com/cmj/Abstract/9000/Immunogenicity_and_safety_of_a_recombinant_fusion.98519.aspx"" style=""color:#006d2c"" target=""_blank"">Shu; Chin Med J 2021</a>"
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase II,Cansino Ad5-nCoV,Vector (non-replicating),876,≥18 (HIV+),1 or 2,Yes,Double-blind,Argentina,24/06/2021,30/09/2022,NCT05005156,https://clinicaltrials.gov/ct2/show/NCT05005156,Recruiting,0,0,0,0,0,no,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV inhaled/intramuscular,Phase I/II,Cansino Ad5-nCoV inhaled/intramuscular,Vector (non-replicating),840,≥18,1 or 2,Yes,"Double-blind, dose-ranging",China,20/04/2021,15/04/2022,NCT04840992,https://clinicaltrials.gov/ct2/show/NCT04840992,Recruiting,0,0,0,0,0,no,NA
"Heterologous - RNA, Vector",BNT162/ChAdOx1-S,Phase II,BNT162/ChAdOx1-S,Heterologous,820,≥50,2,Yes,Single-blind,UK,08/02/2021,05/11/2022,ISRCTN69254139,https://www.isrctn.com/ISRCTN69254139,No longer recruiting,1,0,0,0,1,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01694-9/fulltext"" style=""color:#006d2c"" target=""_blank"">Liu; Lancet 2021</a>"
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Not specified,BioNTech BNT162 (b2),RNA,800,≥18,2,No,Open-label,Belgium,22/03/2021,31/03/2022,NCT04880174,https://clinicaltrials.gov/ct2/show/NCT04880174,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID/University of Oxford/AstraZeneca/Novavax,BNT162/mRNA-1273/ChAdOx1-S/NVX-CoV2373,Phase II,BNT162/mRNA-1273/ChAdOx1-S/NVX-CoV2373,RNA/Vector (non-replicating)/Protein subunit,800,18–45 (pregnant),2,Yes,Single-blind,UK,01/06/2021,01/08/2023,ISRCTN15279830,https://www.isrctn.com/ISRCTN15279830,Recruiting,0,1,0,0,1,no,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase II,Clover SCB-2019,Protein subunit,800,≥18,2,Yes,Double-blind,China,01/08/2021,01/10/2021,NCT04954131,https://clinicaltrials.gov/ct2/show/NCT04954131,Not yet recruiting,0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273,Not specified,Moderna mRNA-1273,RNA,791,≥18 (cancer),2,No,Open-label,Netherlands,08/01/2021,04/06/2021,NCT04715438,https://clinicaltrials.gov/ct2/show/NCT04715438,"Active, not recruiting",0,0,0,0,0,no,NA
Bio Farma/Baylor College of Medicine,Protein subunit vaccine,Phase I/II,Bio Farma protein subunit vaccine,Protein subunit,780,≥18,2,Yes,"Observer-blind, dose-ranging",Indonesia,01/10/2021,31/01/2022,NCT05067894,https://clinicaltrials.gov/ct2/show/NCT05067894,Not yet recruiting,0,0,0,0,0,no,NA
Bharat Biotech/ICMR/National Institute of Virology,Covaxin,Phase I/II,Bharat Covaxin,Inactivated,755,12–65,2,Yes,Double-blind,India,15/07/2020,31/07/2020,NCT04471519,https://clinicaltrials.gov/ct2/show/NCT04471519,"Active, not recruiting",0,0,1,0,0,yes,"<a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30942-7/fulltext"" style=""color:#006d2c"" target=""_blank"">Ella; Lancet Infect Dis 2020</a><br><a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00070-0/fulltext"" style=""color:#006d2c"" target=""_blank"">Ella; Lancet Infect Dis 2021</a>"
Sinovac,CoronaVac,Phase I/II,Sinovac CoronaVac,Inactivated,744,18–59,2,Yes,"Double-blind, dose-ranging",China,16/04/2020,10/07/2020,NCT04352608,https://clinicaltrials.gov/ct2/show/NCT04352608,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30843-4/fulltext"" style=""color:#006d2c"" target=""_blank"">Zhang; Lancet Infect Dis 2020</a><br><a href=""https://www.medrxiv.org/content/10.1101/2021.07.23.21261026v1"" style=""color:#006d2c"" target=""_blank"">Pan; medRxiv 2021</a>"
University of Hong Kong/Jiangsu Provincial CDC/Beijing Wantai Biological Pharmacy/Xiamen University,DelNS1-nCoV-RBD,Phase II,BWBP DelNS1-nCoV-RBD,Vector (replicating),720,≥18,2,Yes,Double-blind,China,17/11/2020,17/12/2021,ChiCTR2000039715,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000039715,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase II/III,BioNTech BNT162 (b2),RNA,700,≥18 (pregnant),2,Yes,Observer-blind,"USA, Brazil, South Africa, others",16/02/2021,15/10/2022,NCT04754594,https://clinicaltrials.gov/ct2/show/NCT04754594,Recruiting,0,1,0,0,0,no,NA
CureVac,CVnCoV,Phase II,CureVac CVnCoV,RNA,700,≥18,2,Yes,"Observer-blind, dose-confirmation","Brazil, Panama, Peru",17/08/2020,17/09/2021,PER-054-20,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=054-20,Enrollment closed,0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase IV,Moderna mRNA-1273,RNA,700,≥18,2,No,Open-label,"USA, Puerto Rico",16/07/2021,30/06/2023,NCT04952402,https://clinicaltrials.gov/ct2/show/NCT04952402,Recruiting,0,0,0,0,0,no,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase I/II,Cansino Ad5-nCoV,Vector (non-replicating),696,18–84,1 or 2,Yes,"Double-blind, dose-ranging",Canada,01/08/2020,20/12/2021,NCT04398147,https://clinicaltrials.gov/ct2/show/NCT04398147,Not yet recruiting,0,0,0,0,0,no,NA
"Heterologous - RNA, Vector",BNT162/ChAdOx1-S,Phase II,BNT162/ChAdOx1-S,Heterologous,676,18–60,2,Yes,Open-label,Spain,24/04/2021,20/05/2021,NCT04860739,https://clinicaltrials.gov/ct2/show/NCT04860739,"Active, not recruiting",1,0,0,0,1,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01420-3/fulltext"" style=""color:#006d2c"" target=""_blank"">Borobia; Lancet 2021</a>"
Instituto Finlay de Vacunas (peptide #1),Soberana 1,Phase I/II,Instituto Finlay de Vacunas Soberana 1,Protein subunit,676,19–80,2,Yes,Double-blind,Cuba,24/08/2020,11/01/2021,IFV/COR/04,https://rpcec.sld.cu/en/trials/RPCEC00000332-En,Recruiting,0,0,0,0,0,no,NA
CureVac,CVnCoV,Phase II,CureVac CVnCoV,RNA,674,≥18,2,Yes,"Observer-blind, dose-confirmation","Panama, Peru",28/09/2020,09/11/2021,NCT04515147,https://clinicaltrials.gov/ct2/show/NCT04515147,"Active, not recruiting",0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273/mRNA-1273.351,Phase II,Moderna mRNA-1273/mRNA-1273.351,RNA,660,≥18,2,Yes,"Observer-blind (part A/B), open-label (part C), dose-confirmation",USA,31/10/2021,01/11/2021,NCT04405076,https://clinicaltrials.gov/ct2/show/NCT04405076,"Active, not recruiting",0,0,0,1,0,yes,"<a href=""https://www.sciencedirect.com/science/article/pii/S0264410X21001535?via%3Dihub"" style=""color:#006d2c"" target=""_blank"">Chu; Vaccine 2021</a><br><a href=""https://www.nature.com/articles/s41591-021-01527-y"" style=""color:#006d2c"" target=""_blank"">Choi; Nat Med 2021</a>"
Novavax,NVX-CoV2373,Phase I/II,Novavax NVX-CoV2373/qNIV combination,Protein subunit,642,50–70,2 or 3,Yes,"Observer-blind, dose-ranging",Australia,08/09/2021,31/03/2022,NCT04961541,https://clinicaltrials.gov/ct2/show/NCT04961541,"Active, not recruiting",0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID,BNT162/mRNA-1273,Phase IV,BNT162/mRNA-1273,RNA,640,≥18 (prior COVID),1 or 2,Yes,Open-label,"USA, Spain, Uganda",25/08/2021,31/07/2022,NCT04969250,https://clinicaltrials.gov/ct2/show/NCT04969250,Recruiting,0,0,0,0,1,no,NA
Inovio Pharmaceuticals/International Vaccine Institute,INO-4800,Phase II,Inovio INO-4800,DNA,640,18–85,2,Yes,"Double-blind, dose-ranging",China,02/12/2020,31/01/2020,ChiCTR2000040146,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000040146,Completed,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2) lyophilised,Phase III,BioNTech BNT162 (b2) lyophilised,RNA,629,18–55,2,Yes,Observer-blind,USA,01/04/2021,29/11/2021,NCT04816669,https://clinicaltrials.gov/ct2/show/NCT04816669,"Active, not recruiting",0,0,0,0,0,no,NA
Nanogen Biopharmaceutical,Nanocovax,Phase I/II,Nanogen Nanocovax,Protein subunit,620,12–75,2,Yes,"Open-label (phase I), double-blind (phase II), dose-ranging",Vietnam,10/12/2020,10/06/2021,NCT04683484,https://clinicaltrials.gov/ct2/show/NCT04683484,Recruiting,0,0,1,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.07.22.21260942v1"" style=""color:#006d2c"" target=""_blank"">Nguyen; medRxiv 2021</a>"
Arcturus/Duke-NUS,LUNAR-COV19/ARCT-021,Phase II,Arcturus ARCT-021,RNA,600,≥18,1 or 2,Yes,"Observer-blind, dose-ranging","USA, Singapore",07/01/2021,30/04/2022,NCT04668339,https://clinicaltrials.gov/ct2/show/NCT04668339,"Active, not recruiting",0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Janssen Pharmaceutical Companies/Moderna/NIAID,BNT162/Ad26.COV2.S/mRNA-1273,Phase II,BNT162/Ad26.COV2.S/mRNA-1273,RNA/Vector (non-replicating),600,≥18 (non-responders with autoimmune disease),1 (boost),Partial,Open-label,USA,13/08/2021,31/01/2022,NCT05000216,https://clinicaltrials.gov/ct2/show/NCT05000216,Recruiting,0,0,0,0,1,no,NA
"Heterologous - RNA, Vector",BNT162/ChAdOx1-S,Phase II,BNT162/ChAdOx1-S,Heterologous,600,≥18,2,Yes,Open-label,Spain,16/04/2021,16/04/2022,EUCTR2021-001978-37-ES,https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001978-37/ES,Ongoing,1,0,0,0,1,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase IV,Oxford ChAdOx1-S,Vector (non-replicating),600,≥18,2,No,Open-label,Swaziland,30/06/2021,31/05/2022,NCT04914832,https://clinicaltrials.gov/ct2/show/NCT04914832,Not yet recruiting,0,0,0,0,0,no,NA
"West China Hospital,/Sichuan University",Protein subunit vaccine,Phase I/II,West China Hospital protein subunit vaccine,Protein subunit,600,6–17,3,Yes,Double-blind,China,15/08/2021,31/10/2021,NCT05013983,https://clinicaltrials.gov/ct2/show/NCT05013983,Not yet recruiting,0,0,1,0,0,no,NA
Wuhan Institute of Biological Products/Sinopharm,WIBP vaccine ,Phase III,WIBP vaccine,Inactivated,600,≥18,2,Yes,Double-blind,Morocco,02/09/2020,31/12/2020,ChiCTR2000039000,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000039000,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2) +/- 20vPnC,Phase III,BioNTech BNT162 (b2) +/- 20vPnC,RNA,582,≥65,1 (boost),Yes,Double-blind,USA,20/05/2021,29/11/2021,NCT04887948,https://clinicaltrials.gov/ct2/show/NCT04887948,"Active, not recruiting",0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID,BNT162/mRNA-1273,Phase IV,BNT162/mRNA-1273,RNA,580,≥18 (haemodialysis),2,No,Open-label,Belgium,27/04/2021,27/10/2021,EUCTR2021-000930-32-BE,https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000930-32/BE,Ongoing,0,0,0,0,1,no,NA
Sinovac,CoronaVac,Phase I/II,Sinovac CoronaVac,Inactivated,552,3–17,2,Yes,"Double-blind, dose-ranging",China,31/10/2020,30/04/2021,NCT04551547,https://clinicaltrials.gov/ct2/show/NCT04551547,Enrolling by invitation,0,0,1,0,0,yes,"<a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00319-4/fulltext"" style=""color:#006d2c"" target=""_blank"">Han; Lancet Infect Dis 2021</a>"
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase II,Janssen Ad26.COV2.S,Vector (non-replicating),550,≥18,1 or 2,Yes,"Double-blind, dose-ranging","Belgium, USA",28/08/2020,15/12/2021,NCT04535453,https://clinicaltrials.gov/ct2/show/NCT04535453,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.08.25.21262569v1"" style=""color:#006d2c"" target=""_blank"">Sadoff; medRxiv 2021</a>"
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2/b2s01),Phase II,BioNTech BNT162 (b2/b2s01),RNA,549,≥18,1 or 2 (boost),Yes,Open-label,Germany,26/07/2021,31/07/2023,NCT04949490,https://clinicaltrials.gov/ct2/show/NCT04949490,Recruiting,0,0,0,1,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase IV,BioNTech BNT162 (b2),RNA,540,≥18 (immunocompromised),2,No,Open-label,Sweden,23/02/2021,31/12/2022,NCT04780659,https://clinicaltrials.gov/ct2/show/NCT04780659,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.09.30.21264377v1"" style=""color:#006d2c"" target=""_blank"">Healy; medRxiv 2021</a>"
ImmunityBio Inc/NantKwest Inc,hAd5-S-Fusion+N-ETSD,Phase I/II,ImmunityBio hAd5-S-Fusion+N-ETSD,Vector (non-replicating),540,18–80,1 (boost),Partial,"Open-label (phase I), double-blind (phase II)",USA,01/06/2021,30/09/2021,NCT04843722,https://clinicaltrials.gov/ct2/show/NCT04843722,Not yet recruiting,0,0,0,0,0,no,NA
ImmunityBio Inc/NantKwest Inc,hAd5-S-Fusion+N-ETSD,Phase I/II,ImmunityBio hAd5-S-Fusion+N-ETSD,Vector (non-replicating),540,18–80,1 (boost),Partial,"Open-label (phase I), double-blind (phase II)",USA,01/06/2021,30/09/2021,NCT04845191,https://clinicaltrials.gov/ct2/show/NCT04845191,Not yet recruiting,0,0,0,0,0,no,NA
"Heterologous - Inactivated, RNA, Vector",BNT162/CoronaVac/ChAdOx1-S,Phase II,BNT162/CoronaVac/ChAdOx1-S,Heterologous,534,≥18,1 (boost),Yes,Double-blind,Chile,08/07/2021,31/08/2021,NCT04992182,https://clinicaltrials.gov/ct2/show/NCT04992182,"Active, not recruiting",1,0,0,0,1,no,NA
Bharat Biotech/ICMR/National Institute of Virology,Covaxin,Phase II/III,Bharat Covaxin,Inactivated,525,2–18,2,No,Open-label,India,26/05/2021,15/08/2021,NCT04918797,https://clinicaltrials.gov/ct2/show/NCT04918797,Recruiting,0,0,1,0,0,no,NA
Moderna/NIAID,mRNA-1273 (fractional intradermal),Phase IV,Moderna mRNA-1273,RNA,525,≥18 (cancer),1 (boost),Yes,Open-label,Belgium,01/11/2021,31/12/2022,NCT05075538,https://clinicaltrials.gov/ct2/show/NCT05075538,Not yet recruiting,0,0,0,0,0,no,NA
"Heterologous - Inactivated, Protein subunit, Vector",CoronaVac/SCB-2019/ChAdOx1-S,Phase II,CoronaVac/SCB-2019/ChAdOx1-S,Heterologous,520,≥18,1 (boost),Yes,Observer-blind,Brazil,01/12/2021,01/04/2022,NCT05087368,https://clinicaltrials.gov/ct2/show/NCT05087368,Not yet recruiting,1,0,0,0,1,no,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,520,3–5,2,Yes,Open-label,China,05/11/2021,05/12/2021,NCT05107557,https://clinicaltrials.gov/ct2/show/NCT05107557,Not yet recruiting,0,0,1,0,0,no,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase II,Cansino Ad5-nCoV,Vector (non-replicating),508,18–60,1,Yes,Double-blind,China,12/04/2020,31/01/2021,NCT04341389,https://clinicaltrials.gov/ct2/show/NCT04341389,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext"" style=""color:#006d2c"" target=""_blank"">Zhu; Lancet 2020</a>"
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase IV,BNT162 (b2),RNA,504,≥18 (kidney transplant),1 (boost),Yes,Open-label,Pending,01/10/2021,28/02/2022,NCT04961229,https://clinicaltrials.gov/ct2/show/NCT04961229,Not yet recruiting,0,0,0,0,0,no,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase III,Cansino Ad5-nCoV,Vector (non-replicating),500,18–85,1,Yes,Double-blind,Russia,11/09/2020,19/06/2021,NCT04540419,https://clinicaltrials.gov/ct2/show/NCT04540419,"Active, not recruiting",0,0,0,0,0,no,NA
"Heterologous - RNA, Vector",mRNA-1273/ChAdOx1-S,Not specified,mRNA-1273/ChAdOx1-S,Heterologous,500,20–65,2,No,Open-label,Taiwan,06/07/2021,19/11/2021,NCT05074368,https://clinicaltrials.gov/ct2/show/NCT05074368,"Active, not recruiting",1,0,0,0,1,no,NA
Organization of Defensive/Innovation and Research,FAKHRAVAC,Phase II,ODIR FAKHRAVAC,Inactivated,500,18–70,2,Yes,Double-blind,Iran,09/06/2021,,IRCT20210206050259N2,https://en.irct.ir/trial/56027,Recruiting,0,0,0,0,0,no,NA
Osaka University/AnGes/Takara Bio,AG0302-COVID19,Phase II/III,AnGes AG0302-COVID19,DNA,500,≥18,2,Yes,Double-blind,Japan,23/11/2020,02/04/2021,NCT04655625,https://clinicaltrials.gov/ct2/show/NCT04655625,"Active, not recruiting",0,0,0,0,0,no,NA
Razi Vaccine and Serum/Research Institute,Razi Cov Pars,Phase II,Razi Cov Pars,Protein subunit,500,18–70,2,Yes,Double-blind,Iran,21/04/2021,,IRCT20201214049709N2,https://en.irct.ir/trial/55238,Recruiting,0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase II,Sinovac CoronaVac,Inactivated,500,3–17,2,Yes,Double-blind,China,03/05/2021,01/08/2021,NCT04884685,https://clinicaltrials.gov/ct2/show/NCT04884685,"Active, not recruiting",0,0,1,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Not specified,BioNTech BNT162 (b1/b2/b2SA),RNA,485,≥18 (immunocompromised),2,No,Open-label,France,16/04/2021,16/04/2023,NCT04844489,https://clinicaltrials.gov/ct2/show/NCT04844489,Recruiting,0,0,0,0,0,no,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase II,Cansino Ad5-nCoV,Vector (non-replicating),481,≥6,2,Yes,"Double-blind, dose-ranging",China,24/09/2020,21/08/2021,NCT04566770,https://clinicaltrials.gov/ct2/show/NCT04566770,Recruiting,0,0,1,0,0,yes,"<a href=""https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab845/6374123"" style=""color:#006d2c"" target=""_blank"">Zhu; Clin Infect Dis 2021</a>"
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase II,AZLB ZF2001,Protein subunit,480,18–85,2 or 3,Yes,"Double-blind, dose-ranging",China,23/03/2021,30/07/2021,NCT04813562,https://clinicaltrials.gov/ct2/show/NCT04813562,Recruiting,0,0,0,0,0,no,NA
Shenzhen Kangtai Biological Products Co Ltd,KCONVAC,Phase II,Shenzhen Kangtai KCONVAC,Inactivated,480,3–17,2 + boost,Yes,Double-blind,China,01/09/2021,31/03/2023,NCT05003466,https://clinicaltrials.gov/ct2/show/NCT05003466,Not yet recruiting,0,0,1,0,0,no,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,480,18–59,2,Yes,Open-label,China,23/03/2021,08/05/2021,NCT04801888,https://clinicaltrials.gov/ct2/show/NCT04801888,Completed,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (a1/b1/b2/c2),Phase I/II,BioNTech BNT162 (a1/b1/b2/c2),RNA,476,18–85,1 or 2,No,"Open-label, dose-ranging",Germany,23/04/2020,30/04/2023,NCT04380701,https://clinicaltrials.gov/ct2/show/NCT04380701,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.nature.com/articles/s41586-021-03653-6"" style=""color:#006d2c"" target=""_blank"">Sahin; Nature 2021</a>"
Sinovac,CoronaVac,Not specified,Sinovac CoronaVac,Inactivated,472,18–59,2,Yes,Not stated,China,09/04/2021,09/05/2022,ChiCTR2100045109,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100045109,Pending,0,0,0,0,0,no,NA
"Institute of Medical Biology,/Chinese Academy of Medical Sciences",Inactivated vaccine,Phase I/II,CAMS vaccine,Inactivated,471,≥60,2,Yes,Double-blind,China,10/07/2020,30/11/2020,NCT04470609,https://clinicaltrials.gov/ct2/show/NCT04470609,Enrolling by invitation,0,0,0,0,0,no,NA
Government Pharmaceutical Organization/Mahidol University/Icahn School of Medicine,NDV-HXP-S,Phase I/II,GPO NDV-HXP-S,Vector (replicating),460,18–75,2,Yes,"Observer-blind, dose-ranging",Thailand,20/03/2021,30/04/2022,NCT04764422,https://clinicaltrials.gov/ct2/show/NCT04764422,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.09.17.21263758v1"" style=""color:#006d2c"" target=""_blank"">Pitisuttithum; medRxiv 2021</a>"
"Heterologous - RNA, Vector",Ad26.COV2.S/mRNA-1273,Phase IV,Ad26.COV2.S/mRNA-1273,Heterologous,460,≥18 (non-responders with kidney transplant),1 or 2 (boost),Yes,Open-label,Pending,01/10/2021,30/11/2022,NCT05030974,https://clinicaltrials.gov/ct2/show/NCT05030974,Not yet recruiting,1,0,0,0,1,no,NA
Instituto Finlay de Vacunas (peptide #1),Soberana 1A/Soberana Plus,Phase II,Instituto Finlay de Vacunas Soberana 1A,Protein subunit,450,19–80,1,Yes,Double-blind,Cuba,17/04/2021,14/06/2021,IFV/COR/11,https://rpcec.sld.cu/trials/RPCEC00000366-En,Pending,0,0,0,0,0,no,NA
Sanofi Pasteur/GSK,CoV2 preS dTM,Phase I/II,Sanofi/GSK CoV2 preS dTM,Protein subunit,440,≥18,1 or 2,Yes,Double-blind,USA,03/09/2020,30/11/2021,NCT04537208,https://clinicaltrials.gov/ct2/show/NCT04537208,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00147-X/fulltext"" style=""color:#006d2c"" target=""_blank"">Goepfert; Lancet Infect Dis 2021</a>"
"Heterologous - RNA, Vector",BNT162/Ad26.COV2.S/mRNA-1273,Not specified,BNT162/Ad26.COV2.S/mRNA-1273,Heterologous,432,18–65,2,Yes,Single-blind,Netherlands,25/06/2021,30/09/2022,NCT04927936,https://clinicaltrials.gov/ct2/show/NCT04927936,Recruiting,1,0,0,0,1,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID,BNT162/mRNA-1273,Phase III,BNT162/mRNA-1273,RNA,431,≥18 (immunocompromised),2,Yes,Open-label,Switzerland,19/04/2021,31/07/2022,NCT04805125,https://clinicaltrials.gov/ct2/show/NCT04805125,"Active, not recruiting",0,0,0,0,1,no,NA
Sinovac,CoronaVac,Phase I/II,Sinovac CoronaVac,Inactivated,422,≥60,2 + boost,Yes,"Double-blind, dose-ranging",China,22/05/2020,28/12/2021,NCT04383574,https://clinicaltrials.gov/ct2/show/NCT04383574,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30987-7/fulltext"" style=""color:#006d2c"" target=""_blank"">Wu; Lancet Infect Dis 2021</a><br><a href=""https://www.medrxiv.org/content/10.1101/2021.08.03.21261544v1"" style=""color:#006d2c"" target=""_blank"">Li; medRxiv 2021</a>"
"Heterologous - Inactivated, Vector",CoronaVac/Ad5-nCoV,Phase I/II,CoronaVac/Ad5-nCoV,Heterologous,420,≥18,1 (boost),Yes,"Open-label, dose-ranging",China,13/09/2021,13/10/2021,NCT05043259,https://clinicaltrials.gov/ct2/show/NCT05043259,Recruiting,1,0,0,0,1,no,NA
IVAC/Dynavax/PATH,COVIVAC,Phase I/II,IVAC COVIVAC,Inactivated,420,18–75,2,Yes,"Observer-blind, dose-ranging",Vietnam,10/03/2021,30/05/2022,NCT04830800,https://clinicaltrials.gov/ct2/show/NCT04830800,Recruiting,0,0,0,0,0,no,NA
Medigen Vaccine Biologics Corporation/NIAID/Dynavax,MVC-COV1901,Phase II,Medigen MVC-COV1901,Protein subunit,420,≥65,2,Yes,"Double-blind, dose-ranging",Taiwan,20/05/2021,31/12/2021,NCT04822025,https://clinicaltrials.gov/ct2/show/NCT04822025,"Active, not recruiting",0,0,0,0,0,no,NA
Heterologous - RNA,BNT162/mRNA-1273,Not specified,BNT162/mRNA-1273,Heterologous,418,≥18,2,Yes,Open-label,France,28/05/2021,02/07/2021,NCT04900467,https://clinicaltrials.gov/ct2/show/NCT04900467,"Active, not recruiting",1,0,0,0,1,no,NA
Moderna/NIAID,mRNA-1273,Phase IV,Moderna mRNA-1273,RNA,414,≥65,1 (boost),Yes,Observer-blind,Canada,15/09/2021,15/11/2021,NCT04978038,https://clinicaltrials.gov/ct2/show/NCT04978038,Not yet recruiting,0,0,0,0,0,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase IV,BIBP BBIBP-CorV,Inactivated,400,≥18 (HIV+),2,No,Open-label,China,08/10/2021,30/06/2022,NCT05075070,https://clinicaltrials.gov/ct2/show/NCT05075070,Recruiting,0,0,0,0,0,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase IV,BIBP BBIBP-CorV,Inactivated,400,≥18 (HIV+),3,No,Open-label,China,08/10/2021,30/12/2022,NCT05075044,https://clinicaltrials.gov/ct2/show/NCT05075044,Recruiting,0,0,0,0,0,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase IV,BIBP BBIBP-CorV,Inactivated,400,≥60 (bronchitis/COPD),2,No,Open-label,China,08/10/2021,30/06/2022,NCT05075083,https://clinicaltrials.gov/ct2/show/NCT05075083,Recruiting,0,0,0,0,0,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase IV,BIBP BBIBP-CorV,Inactivated,400,≥60 (bronchitis/COPD),2,No,Open-label,China,08/10/2021,30/06/2022,NCT05075057,https://clinicaltrials.gov/ct2/show/NCT05075057,Recruiting,0,0,0,0,0,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase IV,BIBP BBIBP-CorV,Inactivated,400,≥60 (HIV),1 (boost),No,Open-label,China,01/12/2021,30/06/2022,NCT05105295,https://clinicaltrials.gov/ct2/show/NCT05105295,Not yet recruiting,0,0,0,0,0,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Phase IV,BIBP BBIBP-CorV,Inactivated,400,≥60 (bronchitis/COPD),1 (boost),No,Open-label,China,01/12/2021,30/06/2022,NCT05104216,https://clinicaltrials.gov/ct2/show/NCT05104216,Not yet recruiting,0,0,0,0,0,no,NA
"Chumakov Center,/Russian Academy of Sciences",CoviVac,Phase I/II,Chumakov CoviVac,Inactivated,400,18–60,2,Yes,Double-blind,Russia,03/10/2020,15/10/2020,NCT05046548,https://clinicaltrials.gov/ct2/show/NCT05046548,"Active, not recruiting",0,0,0,0,0,no,NA
"Heterologous - Inactivated, RNA",BNT162/CoronaVac,Phase IV,BNT162/CoronaVac,Heterologous,400,≥18,1 (boost),Yes,Double-blind,Hong Kong,05/10/2021,31/03/2023,NCT05057169,https://clinicaltrials.gov/ct2/show/NCT05057169,Not yet recruiting,1,0,0,0,1,no,NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase II,Janssen Ad26.COV2.S,Vector (non-replicating),400,18–45 (pregnant),1 or 2,Yes,Open-label,"USA, Brazil, South Africa",27/08/2021,16/01/2023,NCT04765384,https://clinicaltrials.gov/ct2/show/NCT04765384,Recruiting,0,1,0,0,0,no,NA
Osaka University/AnGes/Takara Bio,AG0302-COVID19 intradermal/intramuscular,Phase I/II,AnGes AG0302-COVID19 intradermal/intramuscular,DNA,400,≥18,2 or 3,Yes,"Open-label, dose-ranging",Japan,29/07/2021,26/03/2022,NCT04993586,https://clinicaltrials.gov/ct2/show/NCT04993586,"Active, not recruiting",0,0,0,0,0,no,NA
Vaxine Pty/Medytox/CinnaGen Co,SpikoGen,Phase II,Vaxine SpikoGen,Protein subunit,400,≥18,2,Yes,Double-blind,Iran,30/05/2021,19/07/2021,NCT04944368,https://clinicaltrials.gov/ct2/show/NCT04944368,"Active, not recruiting",0,0,0,0,0,no,NA
Walvax Biotech/PLA Academy of Military Sciences/Suzhou Abogen Biosciences,ARCoV,Phase II,Walvax ARCoV,RNA,400,18–59,Not stated,Yes,Single-blind,China,01/11/2021,31/03/2022,ChiCTR2100041855,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100041855,Recruiting,0,0,0,0,0,no,NA
Medigen Vaccine Biologics Corporation/NIAID/Dynavax,MVC-COV1901,Phase II,Medigen MVC-COV1901,Protein subunit,399,20–64,2,No,Open-label,Taiwan,02/08/2021,30/11/2021,NCT05038618,https://clinicaltrials.gov/ct2/show/NCT05038618,"Active, not recruiting",0,0,0,0,0,no,NA
Medigen Vaccine Biologics Corporation/NIAID/Dynavax,MVC-COV1901,Phase II,Medigen MVC-COV1901,Protein subunit,399,12–18,2,Yes,Double-blind,Taiwan,22/07/2021,31/12/2021,NCT04951388,https://clinicaltrials.gov/ct2/show/NCT04951388,"Active, not recruiting",0,0,1,0,0,no,NA
"Heterologous - RNA, Vector",Ad26.COV2.S/mRNA-1273,Phase III,Ad26.COV2.S/mRNA-1273,Heterologous,386,≥18 (transplant recipients),1 (boost),Yes,Open-label,Spain,01/09/2021,30/09/2022,NCT05048940,https://clinicaltrials.gov/ct2/show/NCT05048940,Not yet recruiting,1,0,0,0,1,no,NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase I,Janssen Ad26.COV2.S,Vector (non-replicating),380,18–65,1,Yes,"Observer-blind, dose-ranging",Netherlands,25/05/2021,01/12/2021,NCT04894305,https://clinicaltrials.gov/ct2/show/NCT04894305,"Active, not recruiting",0,0,0,0,0,no,NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase II,Janssen Ad26.COV2.S,Vector (non-replicating),367,≥18,1 or 2,Yes,"Double-blind, dose-ranging",Germany,02/09/2020,02/01/2022,EUCTR2020-002584-63-DE,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-002584-63/DE,Ongoing,0,0,0,0,0,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Not specified,BIBP BBIBP-CorV,Inactivated,360,18–59 (airline staff),2,Yes,Not stated,China,28/09/2020,27/03/2021,ChiCTR2100041705,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100041705,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.08.06.21261696v1.full-text"" style=""color:#006d2c"" target=""_blank"">Feng; medRxiv 2021</a>"
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Not specified,BIBP BBIBP-CorV,Inactivated,360,18–59 (security personnel),2,Yes,Not stated,China,28/09/2020,27/03/2021,ChiCTR2100041706,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100041706,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.08.06.21261696v1.full-text"" style=""color:#006d2c"" target=""_blank"">Feng; medRxiv 2021</a>"
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Not specified,BIBP BBIBP-CorV,Inactivated,360,18–59 (healthcare workers),2,Yes,Not stated,China,28/09/2020,27/03/2021,ChiCTR2100041704,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100041704,Completed,0,0,0,0,0,no,NA
Biological E Ltd,BECOV,Phase I/II,Biological E Ltd BECOV,Protein subunit,360,18–65,2 or 3,Yes,Open-label,India,16/11/2020,16/01/2022,CTRI/2020/11/029032,http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329&EncHid=&userName=covid-19%20vaccine,"Active, not recruiting",0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase II,BioNTech BNT162 (b2),RNA,360,≥2 (immunocompromised),3,No,Open-label,"USA, Brazil, Germany",30/01/2021,18/02/2023,NCT04895982,https://clinicaltrials.gov/ct2/show/NCT04895982,Not yet recruiting,0,0,1,0,0,no,NA
"Heterologous - Inactivated, Protein subunit",ZF2001,Not specified,AZLB ZF2001,Heterologous,360,≥18,1 (boost),No,Open-label,China,31/08/2021,30/09/2021,NCT05089045,https://clinicaltrials.gov/ct2/show/NCT05089045,Completed,1,0,0,0,0,no,NA
"Heterologous - Inactivated, Vector",BBIBP-CorV/ChAdOx1-S,Phase II,BBIBP-CorV/ChAdOx1-S,Heterologous,360,18–65,2,Yes,Observer-blind,Mozambique,01/09/2021,30/10/2022,NCT04998240,https://clinicaltrials.gov/ct2/show/NCT04998240,Not yet recruiting,1,0,0,0,1,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase IV,Oxford ChAdOx1-S,Vector (non-replicating),360,≥18 (immunocompromised),2,No,Open-label,"Colombia, India, Thailand, Ukraine",22/12/2021,29/09/2022,NCT05057897,https://clinicaltrials.gov/ct2/show/NCT05057897,Not yet recruiting,0,0,0,0,0,no,NA
"Heterologous - RNA, Vector",Gam-COVID-Vac/mRNA-1273/ChAdOx1-S,Phase II,Gam-COVID-Vac/mRNA-1273/ChAdOx1-S,Heterologous,348,21–65,2,Yes,Single-blind,Argentina,30/07/2021,30/08/2021,NCT05027672,https://clinicaltrials.gov/ct2/show/NCT05027672,"Active, not recruiting",1,0,0,0,1,no,NA
GeneOne Life Science,GLS-5310,Phase I/II,GeneOne GLS-5310,DNA,345,19–65,2,Yes,"Double-blind, dose-ranging",Republic of Korea,23/12/2020,31/07/2022,NCT04673149,https://clinicaltrials.gov/ct2/show/NCT04673149,Not yet recruiting,0,0,0,0,0,no,NA
Sanofi Pasteur/Translate Bio,LNP-mRNA vaccine,Phase I/II,Sanofi/Translate LNP-mRNA vaccine,RNA,333,≥18,1 or 2,Yes,"Open-label (sentinel), observer-blind (full), dose-ranging","USA, Australia, Brazil, Honduras",12/03/2021,02/11/2022,NCT04798027,https://clinicaltrials.gov/ct2/show/NCT04798027,Recruiting,0,0,0,0,0,no,NA
Scientific and Technological Research Council (VLP),VLP vaccine,Phase II,STRC VLP vaccine,Virus-like particle,330,18–59,2,Yes,Double-blind,Turkey,26/06/2021,31/12/2021,NCT04962893,https://clinicaltrials.gov/ct2/show/NCT04962893,Recruiting,0,0,0,1,0,no,NA
SK Biosciences (peptide #1),GBP510,Phase I/II,SK Biosciences GBP510,Protein subunit,328,19–85,2,Yes,"Observer-blind, dose-ranging",Republic of Korea,03/02/2021,28/07/2021,NCT04750343,https://clinicaltrials.gov/ct2/show/NCT04750343,"Active, not recruiting",0,0,0,0,0,no,NA
Imperial College London,LNP-nCoVsaRNA,Phase I,Imperial LNP-nCoVsaRNA,RNA,320,18–75,2,Partial,"Open-label (A), observer-blind (B), dose-ranging",UK,16/06/2020,31/07/2021,ISRCTN17072692,http://www.isrctn.com/ISRCTN17072692,No longer recruiting,0,0,0,0,0,no,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase III,AZLB ZF2001,Protein subunit,300,≥18,3,Yes,Open-label,China,03/09/2021,19/11/2021,NCT05107375,https://clinicaltrials.gov/ct2/show/NCT05107375,Recruiting,0,0,0,0,0,no,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase III,Clover SCB-2019,Protein subunit,300,≥18 (chronic inflammatory disease),2,Yes,Double-blind,"South Africa, Ukraine",13/09/2021,28/10/2022,NCT05012787,https://clinicaltrials.gov/ct2/show/NCT05012787,Not yet recruiting,0,0,0,0,0,no,NA
"Heterologous - Inactivated, Vector",Ad5-nCoV/CoronaVac,Phase IV,Ad5-nCoV/CoronaVac,Heterologous,300,18–59,1 (boost),Yes,Observer-blind,China,25/05/2021,25/07/2021,NCT04892459,https://clinicaltrials.gov/ct2/show/NCT04892459,"Active, not recruiting",1,0,0,0,1,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.09.03.21263062v1"" style=""color:#006d2c"" target=""_blank"">Li; medRxiv 2021</a>"
"Heterologous - Inactivated, Vector",BBIBP-CorV/Ad5-nCoV,Phase IV,BBIBP-CorV/Ad5-nCoV,Heterologous,300,≥60,2 or 3,Yes,Observer-blind,China,26/08/2021,26/11/2021,NCT04952727,https://clinicaltrials.gov/ct2/show/NCT04952727,Recruiting,1,0,0,0,1,no,NA
Heterologous - RNA,BNT162/mRNA-1273,Phase II/III,BNT162/mRNA-1273,Heterologous,300,≥18 (kidney disease),1 (boost),Yes,Double-blind,Canada,30/09/2021,30/09/2022,NCT05022329,https://clinicaltrials.gov/ct2/show/NCT05022329,Recruiting,1,0,0,0,1,no,NA
Moderna/NIAID,mRNA-1273 +/- Fluzone,Phase II,Moderna mRNA-1273 +/- Fluzone,RNA,300,≥65,1 (boost),Yes,Open-label,USA,16/07/2021,02/02/2022,NCT04969276,https://clinicaltrials.gov/ct2/show/NCT04969276,Recruiting,0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase II,Oxford ChAdOx1-S,Vector (non-replicating),300,6–17,2,Yes,Single-blind,UK,15/02/2021,30/09/2022,ISRCTN15638344,https://www.isrctn.com/ISRCTN15638344,No longer recruiting,0,0,1,0,0,no,NA
CureVac,CVnCoV,Phase I,CureVac CVnCoV,RNA,280,18–60,2,Yes,"Open-label (phase I), single-blind (phase II), dose-ranging","Belgium, Germany",18/06/2020,31/01/2022,NCT04449276,https://clinicaltrials.gov/ct2/show/NCT04449276,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://link.springer.com/article/10.1007%2Fs00508-021-01922-y"" style=""color:#006d2c"" target=""_blank"">Kremsner; Wien Klin Wochenschr 2021</a>"
EuBiologics Co Ltd,EuCorVac-19,Phase I/II,EuBiologicals EuCorVac-19,Protein subunit,280,19–75,2,Yes,"Observer-blind, dose-ranging",Republic of Korea,23/02/2021,31/03/2022,NCT04783311,https://clinicaltrials.gov/ct2/show/NCT04783311,Recruiting,0,0,0,0,0,no,NA
SpyBiotech/Accelagen Pty/Serum Institute of India,RBD-HBsAg VLP vaccine,Phase I/II,SpyBiotech RBD-HBsAg VLP,Virus-like particle,280,18–79,1 or 2,Yes,"Observer-blind, dose-ranging",Australia,22/08/2020,30/03/2021,ACTRN12620000817943,https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380145&isReview=true,Recruiting,0,0,0,0,0,no,NA
Medigen Vaccine Biologics Corporation/NIAID/Dynavax,MVC-COV1901,Phase II,Medigen MVC-COV1901,Protein subunit,274,≥20,2,No,Open-label,Taiwan,19/07/2021,31/12/2021,NCT05048849,https://clinicaltrials.gov/ct2/show/NCT05048849,"Active, not recruiting",0,0,0,0,0,no,NA
Sinovac,CoronaVac,Phase IV,Sinovac CoronaVac,Inactivated,270,≥18,2,Yes,Open-label,China,09/07/2021,31/12/2021,NCT04953325,https://clinicaltrials.gov/ct2/show/NCT04953325,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase II,BioNTech BNT162 (b2),RNA,267,≥18 (history of SARS-CoV-2),1 or 2,No,Open-label,France,08/03/2021,29/06/2021,NCT04824638,https://clinicaltrials.gov/ct2/show/NCT04824638,"Active, not recruiting",0,0,0,0,0,no,NA
Institut Pasteur/Themis/University of Pittsburg/Merck,V591/TMV-083,Phase I/II,Themis V591/TMV-083,Vector (replicating),263,≥18,1 or 2,Yes,"Double-blind, dose-ranging","USA, Austria, Belgium",27/08/2020,05/03/2021,NCT04498247,https://clinicaltrials.gov/ct2/show/NCT04498247,Terminated,0,0,0,0,0,no,NA
SK Biosciences (peptide #1),GBP510,Phase I/II,SK Biosciences GBP510,Protein subunit,260,19–85,2,Yes,"Observer-blind, dose-ranging",Republic of Korea,20/01/2021,30/07/2021,NCT04742738,https://clinicaltrials.gov/ct2/show/NCT04742738,"Active, not recruiting",0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase I/II,Oxford ChAdOx1-S,Vector (non-replicating),256,≥18,1 or 2,Yes,Double-blind,Japan,23/08/2020,15/11/2021,NCT04568031,https://clinicaltrials.gov/ct2/show/NCT04568031,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.ijidonline.com/article/S1201-9712(21)00818-3/fulltext"" style=""color:#006d2c"" target=""_blank"">Asano; Int J infect Dis 2021</a>"
SpyBiotech/Accelagen Pty/Serum Institute of India,RBD-HBsAg VLP vaccine,Phase I/II,SpyBiotech RBD-HBsAg VLP,Virus-like particle,255,18–79,1 or 2,Yes,"Observer-blind, dose-ranging",Australia,09/12/2020,,ACTRN12620001308987,https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620001308987,Not yet recruiting,0,0,0,0,0,no,NA
Erciyes University (inactivated),TURKOVAC,Phase II,Erciyes TURKOVAC,Inactivated,250,18–64,2,Yes,"Double-blind, dose-ranging",Turkey,10/02/2021,30/04/2021,NCT04824391,https://clinicaltrials.gov/ct2/show/NCT04824391,Recruiting,0,0,0,0,0,no,NA
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase I,Janssen Ad26.COV2.S,Vector (non-replicating),250,≥20,2,Yes,"Double-blind, dose-ranging",Japan,11/08/2020,22/02/2021,NCT04509947,https://clinicaltrials.gov/ct2/show/NCT04509947,"Active, not recruiting",0,0,0,0,0,no,NA
Research Institute for/Biological Safety Problems (inactivated),QazCovid-in,Phase I/II,RIBSP QazCovid-in,Inactivated,244,≥18,1 or 2,Yes,Single-blind,Kazakhstan,19/09/2020,25/11/2020,NCT04530357,https://clinicaltrials.gov/ct2/show/NCT04530357,Completed,0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00358-8/fulltext"" style=""color:#006d2c"" target=""_blank"">Zakarya; EClinicalMedicine 2021</a>"
Research Institute for/Biological Safety Problems (subunit),QazCoVac-P,Phase I/II,RIBSP QazCoVac-P,Protein subunit,244,≥18,1 or 2,Yes,"Single-blind (phase I), open-label (phase II)",Kazakhstan,15/06/2021,31/12/2021,NCT04930003,https://clinicaltrials.gov/ct2/show/NCT04930003,"Active, not recruiting",0,0,0,0,0,no,NA
Adimmune Corporation,AdimrSC-2f,Phase I/II,Adimmune AdimrSC-2f,Protein subunit,240,18–60,3,Yes,"Double-blind, dose-ranging",Indonesia,01/12/2021,30/09/2022,NCT05104489,https://clinicaltrials.gov/ct2/show/NCT05104489,Not yet recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase IV,BioNTech BNT162 (b2),RNA,240,≥18 (immunocompromised),2,No,Open-label,France,29/03/2021,31/03/2022,NCT04952766,https://clinicaltrials.gov/ct2/show/NCT04952766,Recruiting,0,0,0,0,0,no,NA
City of Hope,COH04S1,Phase II,City of Hope COH04S1,Vector (replicating),240,≥18 (blood cancer),2,Yes,Observer-blind,USA,27/09/2021,01/06/2023,NCT04977024,https://clinicaltrials.gov/ct2/show/NCT04977024,Recruiting,0,0,0,0,0,no,NA
German Center for Infection Research (DZIF)/IDT Biologika GmbH/Ludwig Maximilian University of Munich,MVA-SARS-2-ST,Phase I/II,DZIF MVA-SARS-2-ST,Vector (non-replicating),240,≥18,2,Yes,"Double-blind (phase II A), open-label (phase Ib, phase II B)",Germany,16/07/2021,01/03/2022,NCT04895449,https://clinicaltrials.gov/ct2/show/NCT04895449,Recruiting,0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase III,Moderna mRNA-1273,RNA,240,≥18 (transplant recipients),2,No,Open-label,USA,16/04/2021,31/03/2023,NCT04860297,https://clinicaltrials.gov/ct2/show/NCT04860297,Recruiting,0,0,0,0,0,no,NA
Novavax,"NVX-CoV2373 (WT, B.1.351, B.1.617.2)",Phase I/II,"Novavax NVX-CoV2373 (WT, B.1.351, B.1.617.2)",Protein subunit,240,18–64,1 or 2,Yes,Observer-blind,Australia,04/10/2021,10/11/2021,NCT05029856,https://clinicaltrials.gov/ct2/show/NCT05029856,Not yet recruiting,0,0,0,1,0,no,NA
Stemirna Therapeutics Co Ltd/Shanghai East Hospital,mRNACOVID-19,Phase I,Stemirna mRNACOVID-19,RNA,240,≥18,1 or 2,Yes,"Double-blind, dose-ranging",China,25/03/2021,25/05/2022,ChiCTR2100045984,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100045984,Recruiting,0,0,0,0,0,no,NA
IAVI/Merck,V590,Phase I,Merck V590,Vector (replicating),232,≥18,1,Yes,"Double-blind, dose-ranging",USA,29/10/2020,18/02/2021,NCT04569786,https://clinicaltrials.gov/ct2/show/NCT04569786,Terminated,0,0,0,0,0,no,NA
Chula Vaccine Research Center/University of Pennsylvania,ChulaCov19,Phase I/II,Chulalongkorn ChulaCov19,RNA,222,18–75,2,Partial,"Open-label, dose-ranging",Thailand,03/05/2021,30/09/2021,NCT04566276,https://clinicaltrials.gov/ct2/show/NCT04566276,Recruiting,0,0,0,0,0,no,NA
Erciyes University (inactivated)/Sinovac,TURKOVAC/CoronaVac,Phase II,TURKOVAC/CoronaVac,Inactivated,222,18–60,1 (boost),Yes,Double-blind,Turkey,12/07/2021,30/12/2021,NCT04979949,https://clinicaltrials.gov/ct2/show/NCT04979949,Recruiting,0,0,0,0,1,no,NA
"Heterologous - Protein subunit, RNA, Vector",MVC-COV1901/mRNA-1273,Phase IV,MVC-COV1901/mRNA-1273,Heterologous,220,20–69,2,Yes,Double-blind,Taiwan,30/09/2021,31/12/2021,NCT05079633,https://clinicaltrials.gov/ct2/show/NCT05079633,Recruiting,1,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase III,Moderna mRNA-1273,RNA,220,≥18 (autoimmune),2,No,Open-label,Canada,11/03/2021,13/06/2021,NCT04806113,https://clinicaltrials.gov/ct2/show/NCT04806113,"Active, not recruiting",0,0,0,0,0,no,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase I,AZLB ZF2001,Protein subunit,216,≥18,2 or 3,Yes,"Double-blind, dose-ranging",China,30/10/2020,07/12/2021,NCT04636333,https://clinicaltrials.gov/ct2/show/NCT04636333,Recruiting,0,0,0,0,0,no,NA
University of Queensland/CSL/Seqirus,Sclamp,Phase I,Queensland Sclamp,Protein subunit,216,≥18,2,Yes,"Double-blind, dose-ranging",Australia,13/07/2020,06/11/2021,NCT04495933,https://clinicaltrials.gov/ct2/show/NCT04495933,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00200-0/fulltext"" style=""color:#006d2c"" target=""_blank"">Chappell; Lancet Infect Dis 2021</a>"
Shionogi,S-268019,Phase I/II,Shionogi S-268019,Protein subunit,214,20–64,2,Yes,Double-blind,Japan,16/12/2020,,jRCT2051200092,https://jrct.niph.go.jp/en-latest-detail/jRCT2051200092,Recruiting,0,0,0,0,0,no,NA
ExpreS2ion/AdaptVac/Radboud University,ABNCoV2,Phase II,ExpreS2ion/AdaptVac ABNCoV2,Virus-like particle,210,≥18,1 or 2,No,Open-label,Germany,19/08/2021,01/12/2021,NCT05077267,https://clinicaltrials.gov/ct2/show/NCT05077267,Recruiting,0,0,0,0,0,no,NA
Genexine Consortium,GX-19,Phase I/II,Genexine GX-19,DNA,210,18–50,2,Yes,"Double-blind, dose-ranging",Republic of Korea,17/06/2020,17/03/2021,NCT04445389,https://clinicaltrials.gov/ct2/show/NCT04445389,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.05.26.21257700v1"" style=""color:#006d2c"" target=""_blank"">Ahn; medRxiv 2021</a>"
KM Biologics Co Ltd,KD-414,Phase I/II,KM Biologics KD-414,Inactivated,210,≥20,2,Yes,Double-blind,Japan,02/03/2021,,jRCT2071200106,https://jrct.niph.go.jp/en-latest-detail/jRCT2071200106,Not recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID,BNT162/mRNA-1273,Phase IV,BNT162/mRNA-1273,RNA,200,≥18 (+/- past COVID),1 or 2,No,Open-label,France,01/10/2021,01/09/2022,NCT05047718,https://clinicaltrials.gov/ct2/show/NCT05047718,Not yet recruiting,0,0,0,0,1,no,NA
Erciyes University (inactivated),TURKOVAC,Phase II,Erciyes TURKOVAC,Inactivated,200,18–64,3,Yes,"Double-blind, dose-ranging",Turkey,20/09/2021,20/09/2022,NCT05035238,https://clinicaltrials.gov/ct2/show/NCT05035238,Not yet recruiting,0,0,0,0,0,no,NA
"Heterologous - Protein subunit, Vector",ChAdOx1-S/MVC-COV1901,Phase IV,ChAdOx1-S/MVC-COV1901,Heterologous,200,20–64,1 (boost),Yes,Open-label,Taiwan,07/10/2021,31/03/2022,NCT05097053,https://clinicaltrials.gov/ct2/show/NCT05097053,Recruiting,1,0,0,0,0,no,NA
"Heterologous - RNA, Vector",Ad26.COV2.S/BNT162,Phase III,Ad26.COV2.S/BNT162,Heterologous,200,≥18 (transplant recipients),1 (boost),Yes,Single-blind,USA,14/09/2021,30/12/2021,NCT05047640,https://clinicaltrials.gov/ct2/show/NCT05047640,Recruitment complete,1,0,0,0,1,no,NA
Moderna/NIAID,mRNA-1273,Phase I/II,Moderna mRNA-1273,RNA,200,≥20,2,Yes,Observer-blind,Japan,21/01/2021,03/03/2022,NCT04677660,https://clinicaltrials.gov/ct2/show/NCT04677660,"Active, not recruiting",0,0,0,0,0,no,NA
Novavax,NVX-CoV2373,Phase I/II,Novavax NVX-CoV2373,Protein subunit,200,≥20,2,Yes,Observer-blind,Japan,24/02/2021,04/04/2022,NCT04712110,https://clinicaltrials.gov/ct2/show/NCT04712110,"Active, not recruiting",0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford ChAdOx1-S,Vector (non-replicating),200,≥18,2,No,Open-label,Egypt,30/08/2021,30/09/2022,NCT05017792,https://clinicaltrials.gov/ct2/show/NCT05017792,Recruiting,0,0,0,0,0,no,NA
"Heterologous - Inactivated, Vector",Gam-COVID-Vac/ChAdOx1-S/BBIBP-CorV,Phase II,Gam-COVID-Vac/ChAdOx1-S/BBIBP-CorV,Heterologous,192,21–65,2,Yes,Single-blind,Argentina,05/07/2021,05/08/2021,NCT04962906,https://clinicaltrials.gov/ct2/show/NCT04962906,Completed,1,0,0,0,1,no,NA
Guangdong Provincial CDC/Gaozhou CDC/Livson Pharmaceutical Group Inc,V-01,Phase I,Guangdong/Gaozhou V-01,Protein subunit,180,≥18,2,Yes,"Double-blind, dose-ranging",China,22/02/2021,30/06/2022,ChiCTR2100045108,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2100045108,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.tandfonline.com/doi/full/10.1080/22221751.2021.1951126"" style=""color:#006d2c"" target=""_blank"">Liao; Emerg Microbes Infect 2021</a>"
Medicago Inc,CoVLP,Phase I,Medicago CoVLP,Virus-like particle,180,18–55,2,Yes,"Open-label, dose-ranging",Canada,10/07/2020,12/09/2020,NCT04450004,https://clinicaltrials.gov/ct2/show/NCT04450004,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.nature.com/articles/s41591-021-01370-1"" style=""color:#006d2c"" target=""_blank"">Ward; Nature Med 2021</a><br><a href=""https://www.medrxiv.org/content/10.1101/2021.08.04.21261507v1"" style=""color:#006d2c"" target=""_blank"">Gobeil; medRxiv 2021b</a>"
Moderna/NIAID,mRNA-1273,Phase II,Moderna mRNA-1273,RNA,180,≥18,2,No,Open-label,France,10/02/2021,01/07/2021,NCT04748471,https://clinicaltrials.gov/ct2/show/NCT04748471,Not yet recruiting,0,0,0,0,0,no,NA
Shenzhen Kangtai Biological Products Co Ltd,KCONVAC,Phase I,Shenzhen Kangtai KCONVAC,Inactivated,180,≥18,2 or 3,Yes,"Double-blind, dose-ranging",China,07/10/2020,30/06/2021,NCT04758273,https://clinicaltrials.gov/ct2/show/NCT04758273,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://journals.lww.com/cmj/Abstract/9000/Immunogenicity_and_safety_of_a_SARS_CoV_2.98627.aspx"" style=""color:#006d2c"" target=""_blank"">Pan; Chin Med J 2021</a>"
Aivita Biomedical Inc,AV-COVID-19,Phase I/II,Aivita AV-COVID-19,Other/Unknown,175,≥18,1,No,"Open-label, dose-ranging",Pending,01/01/2022,30/06/2022,NCT04386252,https://clinicaltrials.gov/ct2/show/NCT04386252,Not yet recruiting,0,0,0,0,0,no,NA
Bharat Biotech,BBV154,Phase I,Bharat BBV154 (intranasal),Vector (non-replicating),175,18–60,1 or 2,Yes,Double-blind,India,01/03/2021,25/06/2021,NCT04751682,https://clinicaltrials.gov/ct2/show/NCT04751682,"Active, not recruiting",0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase II,mRNA-1273,RNA,171,≥18 (non-responders with haematologic malignancies),1 (boost),No,Open-label,USA,17/08/2022,31/01/2022,NCT05028374,https://clinicaltrials.gov/ct2/show/NCT05028374,Recruiting,0,0,0,0,0,no,NA
Genexine Consortium,GX-19,Phase I/II,Genexine GX-19,DNA,170,18–55,2,Yes,Double-blind,Republic of Korea,30/12/2020,30/05/2021,NCT04715997,https://clinicaltrials.gov/ct2/show/NCT04715997,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.05.26.21257700v1"" style=""color:#006d2c"" target=""_blank"">Ahn; medRxiv 2021</a>"
Walvax Biotech/PLA Academy of Military Sciences/Suzhou Abogen Biosciences,ARCoV,Phase I,Walvax ARCoV,RNA,168,18–80,Not stated,Yes,"Blinding not stated, dose-ranging",China,25/06/2020,31/12/2021,ChiCTR2000034112,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000034112,Pending,0,0,0,0,0,no,NA
"West China Hospital,/Sichuan University",Protein subunit vaccine,Phase I,West China Hospital protein subunit vaccine,Protein subunit,168,≥18,2 or 3,Yes,"Double-blind, dose-ranging",China,28/08/2020,28/10/2020,NCT04530656,https://clinicaltrials.gov/ct2/show/NCT04530656?,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.nature.com/articles/s41392-021-00692-3"" style=""color:#006d2c"" target=""_blank"">Meng; Signal Transduct Target Ther 2021</a>"
Biocad,BCD-250,Phase I/II,Biocad BCD-250,Vector (non-replicating),160,18–60,1,Yes,"Open-label (stage 1), double-blind (stage 2), dose-ranging",Russia,10/08/2021,31/08/2022,NCT05037188,https://clinicaltrials.gov/ct2/show/NCT05037188,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase I/II,BioNTech BNT162 (b2),RNA,160,20–85,2,Yes,Observer-blind,Japan,21/10/2020,24/11/2021,NCT04588480,https://clinicaltrials.gov/ct2/show/NCT04588480,"Active, not recruiting",0,0,0,0,0,no,NA
Inovio Pharmaceuticals/International Vaccine Institute,INO-4800,Phase I/II,Inovio INO-4800,DNA,160,19–64,2,Yes,"Open-label (A), double-blind (B), dose-ranging",Republic of Korea,15/07/2020,22/02/2022,NCT04447781,https://clinicaltrials.gov/ct2/show/NCT04447781,Recruiting,0,0,0,0,0,no,NA
Takis/Applied DNA Sciences/Evvivax/Rottapharm Biotech,COVID-eVax,Phase I/II,Takis COVID-eVax,DNA,160,≥18,Not stated,No,"Open-label, dose-ranging",Italy,03/02/2021,03/02/2022,2020-003734-20,https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003734-20/IT#E,Ongoing,0,0,0,0,0,no,NA
Takis/Applied DNA Sciences/Evvivax/Rottapharm Biotech,COVID-eVax,Phase I/II,Takis COVID-eVax,DNA,160,18–65,1 or 2,No,"Open-label, dose-ranging",Italy,25/02/2021,31/12/2021,NCT04788459,https://clinicaltrials.gov/ct2/show/NCT04788459,Recruiting,0,0,0,0,0,no,NA
Vaccibody,VB10.2129/VB10.2210,Phase I/II,Vaccibody VB10.2129/VB10.2210,DNA,160,18–60,1 or 2,No,"Open-label, dose-ranging",Norway,27/10/2021,30/06/2022,NCT05069623,https://clinicaltrials.gov/ct2/show/NCT05069623,Recruiting,0,0,0,0,0,no,NA
Valneva/Dynavax,VLA2001,Phase I/II,Valneva VLA2001,Inactivated,153,18–55,2,Yes,"Open-label (phase I), double-blind (phase II), dose-ranging",UK,16/12/2020,26/02/2021,NCT04671017,https://clinicaltrials.gov/ct2/show/NCT04671017,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.08.13.21262021v1"" style=""color:#006d2c"" target=""_blank"">Lazarus; medRxiv 2021</a>"
University of Tokyo/Daiichi-Sankyo,DS-5670a,Phase I/II,Daiichi-Sankyo DS-5670a,RNA,152,20–74,2,Yes,"Double-blind, dose-ranging",Japan,15/03/2021,31/07/2022,NCT04821674,https://clinicaltrials.gov/ct2/show/NCT04821674,"Active, not recruiting",0,0,0,0,0,no,NA
BioNet Asia,COVIGEN,Phase I,BioNet Asia COVIGEN,DNA,150,18–75,2,Yes,"Double-blind, dose-ranging",Australia,15/02/2021,30/06/2022,NCT04742842,https://clinicaltrials.gov/ct2/show/NCT04742842,Not yet recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162/mRNA-1273,Phase IV,BioNTech BNT162 (b2),RNA,150,18–55,2,Yes,"Observer-blind, dose-ranging",Belgium,10/05/2021,30/07/2021,NCT04852861,https://clinicaltrials.gov/ct2/show/NCT04852861,Enrolling by invitation,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase I/II,BioNTech BNT162 (b2),RNA,150,1–15 (leukaemia),2,No,Open-label,France,01/08/2021,30/04/2022,NCT04969601,https://clinicaltrials.gov/ct2/show/NCT04969601,Not yet recruiting,0,0,1,0,0,no,NA
Cellid Co Ltd/IAVI,AdCLD-CoV19,Phase I/II,Cellid AdCLD-CoV19,Vector (replicating),150,19–64,1,Yes,"Open-label, dose-ranging",Republic of Korea,29/12/2020,09/07/2021,NCT04666012,https://clinicaltrials.gov/ct2/show/NCT04666012,"Active, not recruiting",0,0,0,0,0,no,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase I,Clover SCB-2019,Protein subunit,150,18–75,2,Yes,"Double-blind, dose-ranging",Australia,19/06/2020,16/10/2020,NCT04405908,https://clinicaltrials.gov/ct2/show/NCT04405908,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00241-5/fulltext"" style=""color:#006d2c"" target=""_blank"">Richmond; Lancet 2021</a><br><a href=""https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab447/6364149"" style=""color:#006d2c"" target=""_blank"">Richmond; J Infect Dis 2021</a>"
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2019,Phase I,Clover SCB-2019,Protein subunit,150,18–75,2,No,Open-label,Australia,19/01/2021,31/05/2023,NCT04932824,https://clinicaltrials.gov/ct2/show/NCT04932824,Recruiting,0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273 (fractional intradermal),Phase I/II,Moderna mRNA-1273,RNA,150,18–30,2,Yes,"Open-label, dose-ranging",Netherlands,01/03/2021,01/08/2022,NL9275,https://www.trialregister.nl/trial/9275,Planned,0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.07.27.21261116v1"" style=""color:#006d2c"" target=""_blank"">Roozen; medRxiv 2021</a>"
Vector Institute (peptide),EpiVacCorona,Phase III,Vector Institute EpiVacCorona,Protein subunit,150,≥60,2,No,Open-label,Russia,19/11/2020,30/01/2021,NCT05021016,https://clinicaltrials.gov/ct2/show/NCT05021016,Completed,0,0,0,0,0,no,NA
Zydus Cadila Healthcare Limited (DNA),ZyCoV-D,Phase I/II,Zydus Cadila ZyCoV-D,DNA,150,18–60,3,Yes,Double-blind,India,19/03/2021,19/09/2021,CTRI/2021/03/032051,http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=53226&EncHid=&userName=covid%20vaccine,Recruiting,0,0,0,0,0,no,NA
CanSino Biological Inc/PLA Academy of Military Sciences,Ad5-nCoV,Phase I,PLA Ad5-nCoV,Vector (non-replicating),149,≥18,1 or 2,No,"Open-label, dose-ranging",China,29/09/2020,31/12/2020,NCT04552366,https://clinicaltrials.gov/ct2/show/NCT04552366,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00396-0/fulltext"" style=""color:#006d2c"" target=""_blank"">Wu; Lancet Infect Dis 2021</a>"
Gritstone Oncology,ChAdV68-S/SAM-LNP-S,Phase I,Gritstone ChAdV68-S/SAM-LNP-S,Vector (non-replicating),147,≥18,2,No,"Open-label, dose-ranging",USA,25/03/2021,19/09/2022,NCT04776317,https://clinicaltrials.gov/ct2/show/NCT04776317,Recruiting,0,0,0,0,0,no,NA
Aivita Biomedical Inc,AV-COVID-19,Phase II,Aivita AV-COVID-19,Other/Unknown,145,≥18,1,Yes,"Double-blind, dose-ranging",Pending,14/04/2021,31/05/2021,NCT05007496,https://clinicaltrials.gov/ct2/show/NCT05007496,Completed,0,0,0,0,0,no,NA
Medicago Inc,CoVLP (MT-2766),Phase I/II,Medicago CoVLP (MT-2766),Virus-like particle,145,≥20,2,Yes,"Observer-blind, dose-ranging",Japan,02/10/2021,31/12/2021,NCT05065619,https://clinicaltrials.gov/ct2/show/NCT05065619,Enrolling by invitation,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b1),Phase I,BioNTech BNT162,RNA,144,18–85,2,Yes,Double-blind,China,28/07/2020,30/09/2020,NCT04523571,https://clinicaltrials.gov/ct2/show/NCT04523571,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.nature.com/articles/s41591-021-01330-9"" style=""color:#006d2c"" target=""_blank"">Li; Nature Med 2021</a>"
Shanghai Zerun Biotechnology Co Ltd/Walvax Biotech,202-CoV,Phase I,Shanghai Zerun 202-CoV,Protein subunit,144,≥18,2,Yes,"Double-blind, dose-ranging",China,12/07/2021,31/12/2021,NCT04982068,https://clinicaltrials.gov/ct2/show/NCT04982068,Recruiting,0,0,0,0,0,no,NA
VBI Vaccines/National Research Council of Canada,VBI-2902a/VBI-2905a,Phase I/II,VBI Vaccines VBI-2902a/VBI-2905a,Virus-like particle,141,≥18,1 or 2,Yes,"Observer-blind, dose-ranging","Canada, Mexico",15/03/2021,30/11/2022,NCT04773665,https://clinicaltrials.gov/ct2/show/NCT04773665,Recruiting,0,0,0,1,0,no,NA
Moderna/NIAID,mRNA-1273/mRNA-1273.351,Phase I,Moderna mRNA-1273/mRNA-1273.351,RNA,135,≥18,2 +/- boost,Yes,"Open-label, dose-ranging",USA,29/03/2021,31/08/2022,NCT04785144,https://clinicaltrials.gov/ct2/show/NCT04785144,"Active, not recruiting",0,0,0,1,0,no,NA
Organization of Defensive/Innovation and Research,FAKHRAVAC,Phase I,ODIR FAKHRAVAC,Inactivated,135,18–55,2,Yes,"Double-blind, dose-ranging",Iran,10/03/2021,,IRCT20210206050259N1,https://en.irct.ir/trial/54133,Recruitment complete,0,0,0,0,0,no,NA
Razi Vaccine and Serum/Research Institute,Razi Cov Pars,Phase I,Razi Cov Pars,Protein subunit,133,18–55,2,Yes,"Double-blind, dose-ranging",Iran,29/01/2021,,IRCT20201214049709N1,https://www.irct.ir/trial/52975,Recruitment complete,0,0,0,0,0,no,NA
Center for Genetic Engineering/and Biotechnology (peptide #1),CIGB-66/Abdala,Phase I/II,CIGB CIGB-66/Abdala,Protein subunit,132,19–54,3,Yes,Double-blind,Cuba,07/12/2020,31/05/2021,RPCEC00000346,https://rpcec.sld.cu/en/trials/RPCEC00000346-En,Pending,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID,BNT162/mRNA-1273,Phase IV,BNT162/mRNA-1273,RNA,130,12–17 (cancer),2,No,Open-label,Netherlands,21/06/2021,04/09/2022,EUCTR2021-003388-90-NL,https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-003388-90/NL,Pending,0,0,1,0,1,no,NA
Meissa Vaccines,MV-014-212,Phase I,Meissa MV-014-212,Vector (replicating),130,18–69,1 or 2,No,"Open-label, dose-ranging",USA,12/04/2021,31/10/2022,NCT04798001,https://clinicaltrials.gov/ct2/show/NCT04798001,Recruiting,0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford ChAdOx1-S,Vector (non-replicating),130,≥18,2,No,Open-label,Egypt,11/02/2021,30/11/2021,NCT04756271,https://clinicaltrials.gov/ct2/show/NCT04756271,Recruiting,0,0,0,0,0,no,NA
City of Hope,COH04S1,Phase I,City of Hope COH04S1,Vector (replicating),129,18–55,1 or 2,Yes,"Double-blind, dose-ranging",USA,11/12/2020,10/11/2022,NCT04639466,https://clinicaltrials.gov/ct2/show/NCT04639466,Recruiting,0,0,0,0,0,no,NA
CureVac,CVnCoV,Phase III,CureVac CVnCoV,RNA,129,≥18 (comorbidities),2,No,Open-label,Belgium,22/04/2021,21/09/2021,NCT04860258,https://clinicaltrials.gov/ct2/show/NCT04860258,Completed,0,0,0,0,0,no,NA
Bharat Biotech/ICMR/National Institute of Virology,Covaxin,Phase I/II,Bharat Covaxin,Inactivated,124,12–65,2,Yes,"Open-label, dose-ranging",India,08/09/2020,08/05/2021,CTRI/2020/09/027674,http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46312&EncHid=&userName=vaccine,Completed,0,0,1,0,0,no,NA
"Heterologous - Inactivated, Vector",Gam-COVID-Vac/ChAdOx1-S/BBIBP-CorV,Phase II,Gam-COVID-Vac/ChAdOx1-S/BBIBP-CorV,Heterologous,120,≥66,2,Yes,Single-blind,Argentina,26/07/2021,26/09/2021,NCT04983537,https://clinicaltrials.gov/ct2/show/NCT04983537,Recruiting,1,0,0,0,1,no,NA
"Heterologous - Protein subunit, Vector",Ad5-nCoV/ZF2001,Phase IV,Ad5-nCoV/ZF2001,Heterologous,120,≥18,2 or 3,Yes,Observer-blind,China,07/04/2021,15/06/2021,NCT04833101,https://clinicaltrials.gov/ct2/show/NCT04833101,"Active, not recruiting",1,0,0,0,1,no,NA
Inovio Pharmaceuticals/International Vaccine Institute,INO-4800,Phase I,Inovio INO-4800,DNA,120,≥18,2 +/- boost,No,"Open-label, dose-ranging",USA,03/04/2020,31/01/2022,NCT04336410,https://clinicaltrials.gov/ct2/show/NCT04336410,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30433-8/fulltext"" style=""color:#006d2c"" target=""_blank"">Tebas; EClinicalMedicine 2020</a>"
Janssen Pharmaceutical Companies,Ad26.COV2.S,Phase IV,Janssen Ad26.COV2.S,Vector (non-replicating),120,≥18,1,No,Open-label,France,20/09/2021,31/10/2021,NCT05037266,https://clinicaltrials.gov/ct2/show/NCT05037266,Recruiting,0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase I,Moderna mRNA-1273,RNA,120,≥18,2 +/- boost,No,"Open-label, dose-ranging",USA,16/03/2020,22/11/2022,NCT04283461,https://clinicaltrials.gov/ct2/show/NCT04283461,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2022483"" style=""color:#006d2c"" target=""_blank"">Jackson; NEJM 2020</a><br><a href=""https://www.nejm.org/doi/full/10.1056/NEJMoa2028436"" style=""color:#006d2c"" target=""_blank"">Anderson; NEJM 2020</a>"
Moderna/NIAID,mRNA-1273,Phase II,Moderna mRNA-1273,RNA,120,≥18 (malignancy),2,No,Open-label,USA,28/04/2021,01/01/2022,NCT04847050,https://clinicaltrials.gov/ct2/show/NCT04847050,Recruiting,0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase IV,Moderna mRNA-1273,RNA,120,≥18 (transplant recipients),1 (boost),Yes,Double-blind,Canada,25/05/2021,30/07/2021,NCT04885907,https://clinicaltrials.gov/ct2/show/NCT04885907,"Active, not recruiting",0,0,0,0,0,no,NA
Walvax Biotech/PLA Academy of Military Sciences/Suzhou Abogen Biosciences,ARCoV,Phase I,Walvax ARCoV,RNA,120,18–59,Not stated,Yes,"Double-blind, dose-ranging",China,28/10/2020,31/12/2021,ChiCTR2000039212,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000039212,Recruiting,0,0,0,0,0,no,NA
University of Hong Kong/Jiangsu Provincial CDC/Beijing Wantai Biological Pharmacy/Xiamen University,DelNS1-nCoV-RBD ,Phase I,BWBP DelNS1-nCoV-RBD,Vector (replicating),115,18–55,2,Yes,"Double-blind, dose-ranging",Hong Kong,29/03/2021,30/09/2022,NCT04809389,https://clinicaltrials.gov/ct2/show/NCT04809389,"Active, not recruiting",0,0,0,0,0,no,NA
Akston Biosciences/University Medical Center Groningen,AKS-452,Phase I/II,Akston AKS-452,Protein subunit,112,18–85,1 or 2,No,"Open-label, dose-ranging",Netherlands,06/04/2021,30/09/2021,NCT04681092,https://clinicaltrials.gov/ct2/show/NCT04681092,Recruiting,0,0,0,0,0,no,NA
"Heterologous - Inactivated, Vector",CAMS vaccine/mRNACOVID-19,Not specified,CAMS vaccine/mRNACOVID-19,Heterologous,112,≥18,1 (boost),No,Open-label,Pending,02/07/2021,02/08/2021,NCT04944381,https://clinicaltrials.gov/ct2/show/NCT04944381,Not yet recruiting,1,0,0,0,1,no,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase II,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),110,≥60,2,No,Open-label,Russia,22/10/2020,30/03/2021,NCT04587219,https://clinicaltrials.gov/ct2/show/NCT04587219,"Active, not recruiting",0,0,0,0,0,no,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase I/II,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),110,≥18,1,No,Open-label,Russia,15/01/2021,20/07/2021,NCT04713488,https://clinicaltrials.gov/ct2/show/NCT04713488,"Active, not recruiting",0,0,0,0,0,no,NA
"Heterologous - Protein subunit, Vector",MVC-COV1901/ChAdOx1-S,Phase II,MVC-COV1901/ChAdOx1-S,Heterologous,110,20–70,2,Yes,Single-blind,Taiwan,15/09/2021,31/08/2022,NCT05054621,https://clinicaltrials.gov/ct2/show/NCT05054621,Recruiting,1,0,0,0,1,no,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase I,Cansino Ad5-nCoV,Vector (non-replicating),108,18–60,1,No,"Open-label, dose-ranging",China,16/03/2020,20/01/2021,NCT04313127,https://clinicaltrials.gov/ct2/show/NCT04313127,Completed,0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31208-3/fulltext"" style=""color:#006d2c"" target=""_blank"">Zhu; Lancet 2020</a><br><a href=""https://www.nature.com/articles/s41421-021-00300-2"" style=""color:#006d2c"" target=""_blank"">Cao; Cell Discov 2021</a>"
Arcturus/Duke-NUS,LUNAR-COV19/ARCT-021,Phase I/II,Arcturus ARCT-021,RNA,106,21–80,Not stated,Yes,"Double-blind, dose-ranging",Singapore,04/08/2020,29/01/2021,NCT04480957,https://clinicaltrials.gov/ct2/show/NCT04480957,Completed,0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.07.01.21259831v1"" style=""color:#006d2c"" target=""_blank"">Low; medRxiv 2021</a>"
Arcturus/Duke-NUS,LUNAR-COV19/ARCT-021,Phase II,Arcturus ARCT-021,RNA,106,≥18,1,No,Open-label,Singapore,04/01/2021,30/06/2022,NCT04728347,https://clinicaltrials.gov/ct2/show/NCT04728347,Recruiting,0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1283/mRNA-1273,Phase I,Moderna mRNA-1283/mRNA-1273,RNA,106,18–55,2,Yes,"Observer-blind, dose-ranging",USA,11/03/2021,13/04/2022,NCT04813796,https://clinicaltrials.gov/ct2/show/NCT04813796,"Active, not recruiting",0,0,0,0,0,no,NA
Kentucky Bioprocessing Inc,KBP-COVID-19,Phase I/II,KBP-COVID-19,Protein subunit,101,18–85,2,Yes,"Observer-blind, dose-ranging","USA, Canada",30/12/2020,31/05/2022,NCT04473690,https://clinicaltrials.gov/ct2/show/NCT04473690,"Active, not recruiting",0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase II,BioNTech BNT162 (b2),RNA,100,18–69 (allergic reaction to dose 1),1 (second),Yes,Double-blind,USA,08/09/2021,30/12/2022,NCT04977479,https://clinicaltrials.gov/ct2/show/NCT04977479,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase II,BioNTech BNT162 (b2),RNA,100,≥18 (non-responders with cancer),1 (boost),No,Open-label,USA,10/08/2021,30/09/2021,NCT05016622,https://clinicaltrials.gov/ct2/show/NCT05016622,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Janssen Pharmaceutical Companies/Moderna/NIAID/University of Oxford/AstraZeneca,BNT162/Ad26.COV2.S/mRNA-1273/ChAdOx1-S,Phase IV,BNT162/Ad26.COV2.S/mRNA-1273/ChAdOx1-S,RNA/Vector (non-replicating),100,18–64 (pregnant),2,Not specified,Open-label,Netherlands,26/05/2021,26/05/2022,EUCTR2021-002327-38-NL,https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-002327-38/NL,Ongoing,0,1,0,0,1,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID,BNT162/mRNA-1273,Phase I,BNT162/mRNA-1273,RNA,100,≥18 (rheumatic disease),2,No,Open-label,USA,15/02/2021,31/12/2021,NCT04839315,https://clinicaltrials.gov/ct2/show/NCT04839315,Recruiting,0,0,0,0,1,no,NA
BioNTech/Pfizer/Fosun Pharma/University of Oxford/AstraZeneca,BNT162/ChAdOx1-S,Phase IV,BNT162/ChAdOx1-S,RNA/Vector (non-replicating),100,≥18 (immunocompromised),2,No,Open-label,Australia,10/05/2021,,ACTRN12621000661875,https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000661875,Recruiting,0,0,0,0,1,no,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase III,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),100,18–60,2,Yes,Double-blind,Belarus,28/09/2020,28/03/2021,NCT04564716,https://clinicaltrials.gov/ct2/show/NCT04564716,"Active, not recruiting",0,0,0,0,0,no,NA
"Heterologous - Inactivated, RNA",BNT162 (b2),Phase IV,BioNTech BNT162 (b2),Heterologous,100,≥30,1 (boost),No,Open-label,Hong Kong,27/09/2021,31/12/2022,NCT05057182,https://clinicaltrials.gov/ct2/show/NCT05057182,Recruiting,1,0,0,0,1,no,NA
Heterologous - Vector,ChAdOx1-S/Gam-COVID-Vac,Phase I/II,ChAdOx1-S/Gam-COVID-Vac,Heterologous,100,≥18,2,Yes,Single-blind,"Belarus, Russia",15/09/2021,08/04/2022,NCT04684446,https://clinicaltrials.gov/ct2/show/NCT04684446,Recruiting,1,0,0,0,1,no,NA
Heterologous - Vector,ChAdOx1-S/Gam-COVID-Vac,Phase II,ChAdOx1-S/Gam-COVID-Vac,Heterologous,100,≥18,2,No,Open-label,Azerbaijan,10/02/2021,09/04/2021,NCT04686773,https://clinicaltrials.gov/ct2/show/NCT04686773,Not yet recruiting,1,0,0,0,1,no,NA
Heterologous - Vector,ChAdOx1-S/Gam-COVID-Vac,Phase I/II,ChAdOx1-S/Gam-COVID-Vac,Heterologous,100,≥18,2,Yes,Single-blind,Pending,17/03/2021,01/05/2021,NCT04760730,https://clinicaltrials.gov/ct2/show/NCT04760730,Not yet recruiting,1,0,0,0,1,no,NA
Jiangsu Rec-Biotechnology Co Ltd,ReCOV,Phase I,Jiangsu ReCOV,Protein subunit,100,18–80,2,Yes,"Double-blind, dose-ranging",New Zealand,18/06/2021,31/12/2021,NCT04818801,https://clinicaltrials.gov/ct2/show/NCT04818801,Recruiting,0,0,0,0,0,no,NA
Shenzhen Geno-Immune Medical Institute/(modified APC),aAPC vaccine,Phase I,SGMI aAPC,Other/Unknown,100,0.5–80,3,No,Open-label,China,15/02/2020,31/07/2023,NCT04299724,https://clinicaltrials.gov/ct2/show/NCT04299724,Recruiting,0,0,1,0,0,no,NA
Shenzhen Geno-Immune Medical Institute/(modified DC),LV-SMENP-DC vaccine,Phase I/II,SGMI LV-SMENP-DC,Other/Unknown,100,0.5–80,1,No,Open-label,China,24/03/2020,31/07/2023,NCT04276896,https://clinicaltrials.gov/ct2/show/NCT04276896,Recruiting,0,0,1,0,0,no,NA
Tetherex Pharmaceuticals,SC-Ad6-1,Phase I,Tetherex SC-Ad6-1,Vector (non-replicating),100,18–60,1 or 2,No,"Open-label, dose-ranging",Australia,28/07/2021,31/12/2021,NCT04839042,https://clinicaltrials.gov/ct2/show/NCT04839042,Recruiting,0,0,0,0,0,no,NA
Vector Institute (peptide),EpiVacCorona,Phase I/II,Vector Institute EpiVacCorona,Protein subunit,100,18–60,2,Yes,"Open-label (phase I), double-blind (phase II)",Russia,27/07/2020,31/05/2021,NCT04527575,https://clinicaltrials.gov/ct2/show/NCT04527575,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.rospotrebnadzor.ru/files/news/1699-10615-2-PB.pdf"" style=""color:#006d2c"" target=""_blank"">Zhu; Ryzhikov; Russian J of Infection and Immunity 2021</a>"
Baiya Phytopharm Co Ltd,Baiya SARS-CoV-2 Vax 1,Phase I,Baiya SARS-CoV-2 Vax 1,Protein subunit,96,18–75,2,Yes,"Open-label, dose-ranging",Pending,01/09/2021,31/12/2021,NCT04953078,https://clinicaltrials.gov/ct2/show/NCT04953078,Not yet recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b3),Phase I/II,BioNTech BNT162 (b3),RNA,96,18–85,2,No,"Open-label, dose-ranging",Germany,09/09/2020,12/03/2021,NCT04537949,https://clinicaltrials.gov/ct2/show/NCT04537949,"Active, not recruiting",0,0,0,0,0,no,NA
Altimmune/University of Alabama at Birmingham,AdCOVID,Phase I,Altimmune AdCOVID,Vector (non-replicating),92,18–55,1 or 2,Yes,"Double-blind, dose-ranging",USA,25/02/2021,28/02/2022,NCT04679909,https://clinicaltrials.gov/ct2/show/NCT04679909,"Active, not recruiting",0,0,0,0,0,no,NA
Avimex/National Council of Science and Technology,Patria,Phase I,Avimex Patria,Inactivated,90,18–55,2,No,"Open-label, dose-ranging",Mexico,20/05/2021,31/08/2021,NCT04871737,https://clinicaltrials.gov/ct2/show/NCT04871737,Recruiting,0,0,0,0,0,no,NA
Institut Pasteur/Themis/University of Pittsburg/Merck,V591/TMV-083,Phase I,Themis V591/TMV-083,Vector (replicating),90,18–55,1 or 2,Yes,"Open-label (does-ranging), observer-blind (treatment phase)","Belgium, France",10/08/2020,12/05/2020,NCT04497298,https://clinicaltrials.gov/ct2/show/NCT04497298,Completed,0,0,0,0,0,no,NA
ReiThera/Leukocare/Univercells,GRAd-COV2,Phase I,ReiThera GRAd-COV2,Vector (non-replicating),90,18–85,1,No,"Open-label, dose-ranging",Italy,10/08/2020,19/05/2021,NCT04528641,https://clinicaltrials.gov/ct2/show/NCT04528641,Completed,0,0,0,0,0,no,NA
University of Washington/NIH/HDT Bio Corp/SENAI CIMATEC,HDT-301,Phase I,HDT Bio Corp HDT-301,RNA,90,18–55,1 or 2,Yes,"Double-blind, dose-ranging",Pending,01/10/2021,30/09/2022,NCT04844268,https://clinicaltrials.gov/ct2/show/NCT04844268,Not yet recruiting,0,0,0,0,0,no,NA
CanSino Biological Inc/Beijing Institute of Biotechnology,Ad5-nCoV,Phase I,Cansino Ad5-nCoV,Vector (non-replicating),89,18–60,1,No,Open-label,China,26/09/2020,25/10/2020,NCT04568811,https://clinicaltrials.gov/ct2/show/NCT04568811,"Active, not recruiting",0,0,0,0,0,no,NA
Center for Genetic Engineering/and Biotechnology (peptide #2),CIGB-669/Mambisa,Phase I/II,CIGB CIGB-669/Mambisa,Protein subunit,88,19–54,3,Yes,Open-label,Cuba,07/12/2020,31/05/2021,RPCEC00000345,https://rpcec.sld.cu/en/trials/RPCEC00000345-En,Pending,0,0,0,0,0,no,NA
Shenzhen Kangtai Biological Products Co Ltd,KCONVAC,Phase I,Shenzhen Kangtai KCONVAC,Inactivated,84,3–17,2,Yes,Double-blind,China,01/08/2021,30/09/2022,NCT05003479,https://clinicaltrials.gov/ct2/show/NCT05003479,Not yet recruiting,0,0,1,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID,BNT162/mRNA-1273,Phase II,BNT162/mRNA-1273,RNA,81,≥18 (transplant recipients),2 +/- boost,No,Open-label,USA,10/08/2021,30/11/2021,NCT04969263,https://clinicaltrials.gov/ct2/show/NCT04969263,"Active, not recruiting",0,0,0,0,1,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase IV,BioNTech BNT162 (b2),RNA,80,≥18 (kidney transplant),2,No,Open-label,Belgium,17/02/2021,17/02/2022,2021-000412-28,https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000412-28/BE,Ongoing,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Not specified,BNT162 (b2),RNA,80,≥18,2,No,Open-label,France,11/03/2021,31/08/2021,NCT04961502,https://clinicaltrials.gov/ct2/show/NCT04961502,Recruiting,0,0,0,0,0,no,NA
CyanVac LLC,CVXGA1,Phase I,CyanVac CVXGA1,Vector (replicating),80,18–75,1,No,"Open-label, dose-ranging",USA,06/08/2021,31/12/2021,NCT04954287,https://clinicaltrials.gov/ct2/show/NCT04954287,Recruiting,0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase II,Moderna mRNA-1273,RNA,80,≥18 (renal transplant),1 (boost),No,Open-label,Pending,01/08/2021,01/12/2021,NCT04930770,https://clinicaltrials.gov/ct2/show/NCT04930770,Not yet recruiting,0,0,0,0,0,no,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase I,AZLB ZF2001,Protein subunit,75,3–17,Not stated,Yes,Double-blind,China,03/07/2021,30/11/2021,NCT04961359,https://clinicaltrials.gov/ct2/show/NCT04961359,Recruiting,0,0,1,0,0,no,NA
Arcturus/Vinbiocare,ARCT-154/ARCT-165/ARCT-021,Phase I/II,Arcturus ARCT-154/ARCT-165/ARCT-021,RNA,72,21–80,1 or 2,Yes,Observer-blind,"USA, Singapore",30/08/2021,31/03/2023,NCT05037097,https://clinicaltrials.gov/ct2/show/NCT05037097,Recruiting,0,0,0,0,0,no,NA
"VIDO-InterVac,/University of Saskatchewan",COVAC-2,Phase I,VIDO COVAC-2,Protein subunit,72,≥18,2,Yes,"Observer-blind, dose-ranging",Canada,10/02/2021,31/10/2022,NCT04702178,https://clinicaltrials.gov/ct2/show/NCT04702178,Recruiting,0,0,0,0,0,no,NA
Adimmune Corporation,AdimrSC-2f,Phase I,Adimmune AdimrSC-2f,Protein subunit,70,20–60,2,Yes,"Open-label, dose-ranging",Taiwan,24/08/2020,20/11/2020,NCT04522089,https://clinicaltrials.gov/ct2/show/NCT04522089,"Active, not recruiting",0,0,0,0,0,no,NA
Bagheiat-allah University of Medical Sciences,AmitisGen,Phase I,Bagheiat-allah AmitisGen,Protein subunit,70,18–50,3,Yes,"Double-blind, dose-ranging",Iran,25/06/2021,,IRCT20210620051639N1,https://en.irct.ir/trial/56987,Recruiting,0,0,0,0,0,no,NA
University Hospital Tübingen,CoVac-1,Phase I/II,Tübingen CoVac-1,Protein subunit,68,≥18 (B-cell deficiency),1 or 2,No,Open-label,Germany,30/06/2021,01/02/2022,NCT04954469,https://clinicaltrials.gov/ct2/show/NCT04954469,Recruiting,0,0,0,0,0,no,NA
Beijing Institute of Biological Products/Sinopharm,BBIBP-CorV,Not specified,BIBP BBIBP-CorV,Inactivated,63,18–59,1 (boost),No,Open-label,China,12/07/2021,01/06/2022,ChiCTR2100048665,https://www.chictr.org.cn/showproj.aspx?proj=129132,Not yet recruiting,0,0,0,0,0,no,NA
Elixirgen Therapeutics/Fujita Health University,EXG-5003,Phase I/II,Elixirgen EXG-5003,RNA,60,20–55,2,Yes,Double-blind,Japan,28/04/2021,31/01/2023,NCT04863131,https://clinicaltrials.gov/ct2/show/NCT04863131,Recruiting,0,0,0,0,0,no,NA
"Heterologous - RNA, Vector",BNT162/mRNA-1273/ChAdOx1-S,Phase II,BNT162/mRNA-1273/ChAdOx1-S,Heterologous,60,≥18 (rituximab),2,Yes,Single-blind,Austria,21/05/2021,,EUCTR2021-002348-57-AT,https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-002348-57/AT,Ongoing,1,0,0,0,1,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.09.05.21263125v1"" style=""color:#006d2c"" target=""_blank"">Bonelli; medRxiv 2021</a>"
"Heterologous - RNA, Vector",BNT162/Ad26.COV2.S/mRNA-1273,Not specified,BNT162/Ad26.COV2.S/mRNA-1273,Heterologous,60,≥18 (multiple sclerosis),1 (boost),Yes,Single-blind,Pending,01/10/2021,31/10/2022,NCT05081271,https://clinicaltrials.gov/ct2/show/NCT05081271,Not yet recruiting,1,0,0,0,1,no,NA
Instituto Finlay de Vacunas (peptide #1),Soberana 1,Phase I,Instituto Finlay de Vacunas Soberana 1,Protein subunit,60,19–59,2 or 3,Yes,"Double-blind, dose-ranging",Cuba,19/10/2020,31/01/2021,IFV/COR/05,https://rpcec.sld.cu/en/trials/RPCEC00000338-En,Recruitment complete,0,0,0,0,0,no,NA
Providence Therapeutics,PTX-COVID19-B,Phase I,Providence Therapeutics PTX-COVID19-B,RNA,60,18–64,2,Yes,"Observer-blind, dose-ranging",Canada,14/01/2021,12/02/2022,NCT04765436,https://clinicaltrials.gov/ct2/show/NCT04765436,"Active, not recruiting",0,0,0,0,0,no,NA
University of Hong Kong/Jiangsu Provincial CDC/Beijing Wantai Biological Pharmacy/Xiamen University,DelNS1-nCoV-RBD,Phase I,BWBP DelNS1-nCoV-RBD,Vector (replicating),60,≥18,Not stated,Yes,Double-blind,China,01/09/2020,31/10/2021,ChiCTR2000037782,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000037782,Pending,0,0,0,0,0,no,NA
Vaxxinity,UB-612,Phase I,Vaxxinity UB-612,Protein subunit,60,20–55,2,No,"Open-label, dose-ranging",Taiwan,25/09/2020,18/01/2021,NCT04545749,https://clinicaltrials.gov/ct2/show/NCT04545749,Completed,0,0,0,0,0,no,NA
Vaxxinity,UB-612,Phase I,Vaxxinity UB-612,Protein subunit,60,20–55,1 (boost),No,"Open-label, dose-ranging",Taiwan,05/08/2021,31/10/2021,NCT04967742,https://clinicaltrials.gov/ct2/show/NCT04967742,Recruiting,0,0,0,0,0,no,NA
Shifa Pharmed,COVIran,Phase I,Shifa Pharmed COVIran,Inactivated,56,18–50,2,Yes,"Double-blind, dose-ranging",Iran,21/12/2020,,IRCT20201202049567N1,https://en.irct.ir/trial/52701,Recruitment complete,0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S (intranasal),Phase I,Oxford ChAdOx1-S (intranasal),Vector (non-replicating),54,18–55,1 or 2,Yes,"Open-label, dose-ranging",UK,01/04/2021,30/04/2022,NCT04816019,https://clinicaltrials.gov/ct2/show/NCT04816019,Recruiting,0,0,0,0,0,no,NA
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase I,AZLB ZF2001,Protein subunit,50,18–59,2,Yes,Double-blind,China,22/06/2020,21/07/2021,NCT04445194,https://clinicaltrials.gov/ct2/show/NCT04445194,Recruiting,0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00127-4/fulltext"" style=""color:#006d2c"" target=""_blank"">Yang; Lancet Infect Dis 2021</a>"
Anhui Zhifei Longcom Biopharmaceutical/Chinese Academy of Sciences,ZF2001,Phase I,AZLB ZF2001,Protein subunit,50,≥60,Not stated,Yes,"Double-blind, dose-ranging",China,19/08/2020,18/12/2020,NCT04550351,https://clinicaltrials.gov/ct2/show/NCT04550351,"Active, not recruiting",0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Not specified,BioNTech BNT162 (b1/b2/b2SA),RNA,50,18–75,2,Yes,Open-label,Israel,24/12/2020,24/10/2021,NCT04842708,https://clinicaltrials.gov/ct2/show/NCT04842708,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase III,BioNTech BNT162 (b2),RNA,50,≥18 (allo-HCT recipients),2,No,Open-label,Belgium,22/03/2021,01/12/2021,NCT04951323,https://clinicaltrials.gov/ct2/show/NCT04951323,Recruiting,0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Phase IV,BioNTech BNT162 (b2),RNA,50,≥18 (allo-HCT recipients),1 (boost),No,Open-label,Belgium,11/03/2021,11/09/2022,EUCTR2021-000673-83,https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000673-83/BE,Ongoing,0,0,0,0,0,yes,"<a href=""https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01190-3"" style=""color:#006d2c"" target=""_blank"">Canti; J Haem Oncol 2021</a>"
Scientific and Technological Research Council (inactivated),Inactivated vaccine,Phase I,STRC inactivated vaccine,Inactivated,50,18–45,2,Yes,"Double-blind, dose-ranging",Turkey,25/04/2021,31/10/2021,NCT04866069,https://clinicaltrials.gov/ct2/show/NCT04866069,Recruiting,0,0,0,0,0,no,NA
SK Biosciences (peptide #2),NBP2001,Phase I,SK Biosciences NBP2001,Protein subunit,50,19–55,2,Yes,"Observer-blind, dose-ranging",Republic of Korea,17/12/2020,30/04/2021,NCT04760743,https://clinicaltrials.gov/ct2/show/NCT04760743,"Active, not recruiting",0,0,0,0,0,no,NA
Codagenix/Serum Institute of India,COVI-VAC,Phase I,Codagenix COVI-VAC,Live-attenuated,48,18–30,1 or 2,Yes,"Double-blind, dose-ranging",UK,11/12/2020,26/06/2021,NCT04619628,https://clinicaltrials.gov/ct2/show/NCT04619628,"Active, not recruiting",0,0,0,0,0,no,NA
OSE Immunotherapeutics,CoVepiT,Phase I,OSE CoVepiT,Protein subunit,48,18–45,2,Yes,Open-label,Belgium,26/05/2021,30/09/2021,NCT04885361,https://clinicaltrials.gov/ct2/show/NCT04885361,Recruiting,0,0,0,0,0,no,NA
Inovio Pharmaceuticals/International Vaccine Institute,INO-4800,Phase I,Inovio INO-4800,DNA,45,18–59,2,Yes,"Double-blind, dose-ranging",China,09/09/2020,13/09/2021,ChiCTR2000038152,http://www.chictr.org.cn/historyversionpuben.aspx?regno=ChiCTR2000038152,Completed,0,0,0,0,0,no,NA
Medigen Vaccine Biologics Corporation/NIAID/Dynavax,MVC-COV1901,Phase I,Medigen MVC-COV1901,Protein subunit,45,20–50,2,No,"Open-label, dose-ranging",Taiwan,07/10/2020,01/06/2021,NCT04487210,https://clinicaltrials.gov/ct2/show/NCT04487210,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.sciencedirect.com/science/article/pii/S2589537021002698"" style=""color:#006d2c"" target=""_blank"">Hsieh; EClinicalMedicine 2021</a>"
VaxForm/Syneos Health,CoV2-OGEN1,Phase I/II,VaxForm CoV2-OGEN1,Other/Unknown,45,18–56,2,No,"Open-label, dose-ranging",New Zealand,30/06/2021,05/10/2021,NCT04893512,https://clinicaltrials.gov/ct2/show/NCT04893512,Recruiting,0,0,0,0,0,no,NA
Erciyes University (inactivated),TURKOVAC,Phase I,Erciyes TURKOVAC,Inactivated,44,18–55,2,Yes,"Double-blind, dose-ranging",Turkey,05/11/2020,01/03/2021,NCT04691947,https://clinicaltrials.gov/ct2/show/NCT04691947,Recruiting,0,0,0,0,0,no,NA
Guangdong Provincial CDC/Gaozhou CDC/Livson Pharmaceutical Group Inc,V-01,Phase I,Guangdong/Gaozhou V-01,Protein subunit,43,≥18,1 (boost),No,Open-label,China,07/08/2021,23/08/2021,NCT05050474,https://clinicaltrials.gov/ct2/show/NCT05050474,"Active, not recruiting",0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma,BNT162 (b2),Not specified,BioNTech BNT162 (b2),RNA,42,18–55,2,No,Open-label,Poland,06/08/2021,02/05/2023,IRCT20210708051820N1,https://en.irct.ir/trial/57414,Recruitment complete,0,0,0,0,0,no,NA
ExpreS2ion/AdaptVac/Radboud University,ABNCoV2,Phase I,ExpreS2ion/AdaptVac ABNCoV2,Virus-like particle,42,18–55,2,No,"Open-label, dose-ranging",Netherlands,11/03/2021,20/12/2021,NCT04839146,https://clinicaltrials.gov/ct2/show/NCT04839146,Recruiting,0,0,0,0,0,no,NA
Imperial College London/MRC–UVRI and LSHTM Uganda Research Unit,LNP-nCoV saRNA-02,Phase I,Imperial LNP-nCoV saRNA-02,RNA,42,18–45,2,No,Open-label,Uganda,01/09/2021,30/06/2022,NCT04934111,https://clinicaltrials.gov/ct2/show/NCT04934111,Not yet recruiting,0,0,0,0,0,no,NA
Cellid Co Ltd/IAVI,AdCLD-CoV19,Phase I,Cellid AdCLD-CoV19,Vector (replicating),40,19–64,1,No,"Open-label, dose-ranging",Republic of Korea,09/09/2021,30/09/2022,NCT05047692,https://clinicaltrials.gov/ct2/show/NCT05047692,Recruiting,0,0,0,0,0,no,NA
Instituto Finlay de Vacunas (peptide #2),Soberana 2,Phase I,Instituto Finlay de Vacunas Soberana 2,Protein subunit,40,19–59,2,No,"Open-label, dose-ranging",Cuba,02/11/2020,06/01/2021,IFV/COR/06,https://rpcec.sld.cu/en/trials/RPCEC00000340-En,Recruitment complete,0,0,0,0,0,no,NA
Scancell Ltd/University of Nottingham/Nottingham Trent University,COVIDITY,Phase I,Scancell COVIDITY,DNA,40,18–59,2 + 2,Yes,"Open-label, dose-ranging",South Africa,30/09/2021,30/04/2022,NCT05047445,https://clinicaltrials.gov/ct2/show/NCT05047445,Recruiting,0,0,0,0,0,no,NA
Vaxine Pty/Medytox/CinnaGen Co,SpikoGen,Phase I,Vaxine SpikoGen,Protein subunit,40,18–65,2,Yes,Double-blind,Australia,30/06/2020,01/02/2021,NCT04453852,https://clinicaltrials.gov/ct2/show/NCT04453852,Completed,0,0,0,0,0,no,NA
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase I/II,Gamaleya Gam-COVID-Vac/Sputnik V,Vector (non-replicating),38,18–60,1 or 2,No,Open-label,Russia,17/06/2020,03/08/2020,NCT04436471,https://clinicaltrials.gov/ct2/show/NCT04436471,Completed,0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext"" style=""color:#006d2c"" target=""_blank"">Logunov; Lancet 2020</a>"
Gamaleya Research Institute,Gam-COVID-Vac/Sputnik V,Phase I/II,Gamaleya Gam-COVID-Vac/Sputnik V (Lyo),Vector (non-replicating),38,18–60,1 or 2,No,Open-label,Russia,17/06/2020,03/08/2020,NCT04437875,https://clinicaltrials.gov/ct2/show/NCT04437875,Completed,0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext"" style=""color:#006d2c"" target=""_blank"">Logunov; Lancet 2020</a>"
Kocak Farma Ilac Ve Kimya San. A.S.,Inactivated vaccine,Phase I,Kocak Farma inactivated vaccine,Inactivated,38,18–55,2,Yes,"Double-blind, dose-ranging",Turkey,19/03/2021,01/06/2021,NCT04838080,https://clinicaltrials.gov/ct2/show/NCT04838080,Recruiting,0,0,0,0,0,no,NA
Entos Pharmaceuticals,Covigenix VAX-001,Phase I/II,Entos Covigenix VAX-001,DNA,36,≥18,2,Yes,"Observer-blind, dose-ranging",Canada,07/04/2021,31/08/2021,NCT04591184,https://clinicaltrials.gov/ct2/show/NCT04591184,"Active, not recruiting",0,0,0,0,0,no,NA
OncoSec Medical Inc/Providence Cancer Institute,CORVax12,Phase I,OncoSec CORVax12,DNA,36,≥18,2,No,Open-label,USA,01/07/2021,31/05/2021,NCT04627675,https://clinicaltrials.gov/ct2/show/NCT04627675,"Active, not recruiting",0,0,0,0,0,no,NA
Scientific and Technological Research Council (VLP),VLP vaccine,Phase I,STRC VLP vaccine,Virus-like particle,36,18–59,2,Yes,"Double-blind, dose-ranging",Turkey,27/03/2021,31/01/2022,NCT04818281,https://clinicaltrials.gov/ct2/show/NCT04818281,Recruiting,0,0,0,0,0,no,NA
University Hospital Tübingen,CoVac-1,Phase I,Tübingen CoVac-1,Protein subunit,36,≥18,1,No,Open-label,Germany,27/11/2020,30/09/2021,NCT04546841,https://clinicaltrials.gov/ct2/show/NCT04546841,"Active, not recruiting",0,0,0,0,0,no,NA
ImmunityBio Inc/NantKwest Inc,hAd5-S-Fusion+N-ETSD,Phase I,ImmunityBio hAd5-S-Fusion+N-ETSD,Vector (non-replicating),35,18–50,2,No,"Open-label, dose-ranging",South Africa,02/03/2021,30/04/2022,NCT04710303,https://clinicaltrials.gov/ct2/show/NCT04710303,Recruiting,0,0,0,0,0,no,NA
Vaxart,VXA-CoV2-1,Phase I,Vaxart VXA-CoV2-1,Vector (non-replicating),35,18–54,2,No,"Open-label, dose-ranging",USA,21/09/2020,10/05/2021,NCT04563702,https://clinicaltrials.gov/ct2/show/NCT04563702,"Active, not recruiting",0,0,0,0,0,no,NA
ImmunityBio Inc/NantKwest Inc,hAd5-S-Fusion+N-ETSD,Phase I,ImmunityBio hAd5-S-Fusion+N-ETSD,Vector (non-replicating),34,18–55,"1, 2 or 3",No,"Open-label, dose-ranging",USA,19/10/2020,19/11/2021,NCT04591717,https://clinicaltrials.gov/ct2/show/NCT04591717,"Active, not recruiting",0,0,0,0,0,yes,"<a href=""https://www.medrxiv.org/content/10.1101/2021.04.05.21254940v1"" style=""color:#006d2c"" target=""_blank"">Sieling; medRxiv 2021</a>"
Shifa Pharmed,COVIran,Phase I,Shifa Pharmed COVIran,Inactivated,32,51–75,2,Yes,Double-blind,Iran,13/03/2021,,IRCT20201202049567N2,https://en.irct.ir/trial/54885,Recruitment complete,0,0,0,0,0,no,NA
DreamTec Research Limited,Bacillus subtilis display vaccine,Not specified,DreamTec Bacillus subtilis display vaccine,Other/Unknown,30,≥25,1 (boost) or 3,No,Open-label,Hong Kong,10/07/2021,20/10/2021,NCT05057923,https://clinicaltrials.gov/ct2/show/NCT05057923,Recruiting,0,0,0,0,0,no,NA
GeneOne Life Science,GLS-5310,Phase I,GeneOne GLS-5310,DNA,30,18–65,2,Yes,"Single-blind, dose-ranging",Puerto Rico,01/11/2021,30/04/2022,NCT05085639,https://clinicaltrials.gov/ct2/show/NCT05085639,Not yet recruiting,0,0,0,0,0,no,NA
Genexine Consortium,GX-19N,Phase I,Genexine GX-19N,DNA,30,55–85,2,No,Open-label,Republic of Korea,16/02/2021,31/07/2021,NCT04915989,https://clinicaltrials.gov/ct2/show/NCT04915989,"Active, not recruiting",0,0,0,0,0,no,NA
German Center for Infection Research (DZIF)/IDT Biologika GmbH/Ludwig Maximilian University of Munich,MVA-SARS-2-S,Phase I,DZIF MVA-SARS-2-S,Vector (non-replicating),30,18–55,2,No,"Open-label, dose-ranging",Germany,05/10/2020,30/09/2021,NCT04569383,https://clinicaltrials.gov/ct2/show/NCT04569383,"Active, not recruiting",0,0,0,0,0,no,NA
HIPRA Scientific,HIPRA vaccine,Phase I/II,HIPRA Scientific vaccine,Protein subunit,30,≥18,2,Yes,"Observer-blind, dose-ranging",Spain,16/08/2021,30/11/2021,NCT05007509,https://clinicaltrials.gov/ct2/show/NCT05007509,"Active, not recruiting",0,0,0,0,0,no,NA
Instituto Finlay de Vacunas (peptide #1),Soberana 1A,Phase I,Instituto Finlay de Vacunas Soberana 1A,Protein subunit,30,19–59,1,No,Open-label,Cuba,09/01/2021,13/02/2021,IFV/COR/07,https://rpcec.sld.cu/en/trials/RPCEC00000349-En,Recruitment complete,0,0,0,0,0,yes,"<a href=""https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(21)00075-2/fulltext"" style=""color:#006d2c"" target=""_blank"">Chang-Monteagudo; Lancet Regional Health 2021</a>"
McMaster University,Ad5-triCoV-Mac/ChAd-triCoV-Mac ,Phase I,McMaster Ad5-triCoV-Mac/ChAd-triCoV/Mac,Vector (non-replicating),30,18–65,1 (boost),Yes,"Open-label, dose-ranging",Canada,29/11/2021,30/06/2023,NCT05094609,https://clinicaltrials.gov/ct2/show/NCT05094609,Not yet recruiting,0,0,0,0,0,no,NA
Osaka University/AnGes/Takara Bio,AG0301-COVID19,Phase I/II,AnGes AG0301-COVID19,DNA,30,20–65,2,No,"Open-label, dose-ranging",Japan,29/06/2020,28/09/2020,NCT04463472,https://clinicaltrials.gov/ct2/show/NCT04463472,Completed,0,0,0,0,0,no,NA
Osaka University/AnGes/Takara Bio,AG0302-COVID19,Phase I/II,AnGes AG0302-COVID19,DNA,30,20–65,2 or 3,Yes,Open-label,Japan,31/08/2020,09/11/2020,NCT04527081,https://clinicaltrials.gov/ct2/show/NCT04527081,Completed,0,0,0,0,0,no,NA
University of Hong Kong/Immuno Cure 3 Ltd,DNA vaccine,Phase I,Immuno Cure 3 DNA vaccine,DNA,30,18–55,2,Yes,Double-blind,Pending,01/11/2021,30/06/2022,NCT05102643,https://clinicaltrials.gov/ct2/show/NCT05102643,Not yet recruiting,0,0,0,0,0,no,NA
Walter Reed Army Institute of Research,SpFN,Phase I,WRAIR SpFN,Protein subunit,29,18–55,2 or 3,Yes,"Double-blind, dose-ranging",USA,05/04/2021,30/10/2022,NCT04784767,https://clinicaltrials.gov/ct2/show/NCT04784767,"Active, not recruiting",0,0,0,0,0,no,NA
Aivita Biomedical Inc,AV-COVID-19,Phase I,Aivita AV-COVID-19,Other/Unknown,27,≥18,1,Yes,"Double-blind, dose-ranging",Indonesia,07/12/2020,31/01/2021,NCT04685603,https://clinicaltrials.gov/ct2/show/NCT04685603,Recruiting,0,0,0,0,0,no,NA
Aivita Biomedical Inc,AV-COVID-19,Phase I,Aivita AV-COVID-19,Other/Unknown,27,≥18,1,Yes,"Open-label, dose-ranging",Indonesia,07/12/2020,13/01/2021,NCT04690387,https://clinicaltrials.gov/ct2/show/NCT04690387,Completed,0,0,0,0,0,no,NA
ImmunityBio Inc/NantKwest Inc,hAd5-S-Fusion+N-ETSD,Phase I,ImmunityBio hAd5-S-Fusion+N-ETSD,Vector (non-replicating),26,18–55,2 or 3,No,Open-label,USA,24/02/2021,30/04/2022,NCT04732468,https://clinicaltrials.gov/ct2/show/NCT04732468,"Active, not recruiting",0,0,0,0,0,no,NA
Symvivo,bacTRL-Spike,Phase I,Symvivo bacTRL-Spike,DNA,24,≥18,1,Yes,"Observer-blind, dose-ranging",Australia,02/11/2020,08/02/2022,NCT04334980,https://clinicaltrials.gov/ct2/show/NCT04334980,"Active, not recruiting",0,0,0,0,0,no,NA
BioNTech/Pfizer/Fosun Pharma/Moderna/NIAID,BNT162/mRNA-1273,Phase IV,BNT162/mRNA-1273,RNA,15,≥18 (pregnant/lactating),2,No,Open-label,Belgium,27/04/2021,27/10/2021,EUCTR2021-000893-27-BE,https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000893-27/BE,Ongoing,0,1,0,0,1,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S (inhaled),Phase I,Oxford ChAdOx1-S,Vector (non-replicating),15,30–55,1,No,"Open-label, dose-ranging",UK,01/09/2021,30/09/2022,NCT05007275,https://clinicaltrials.gov/ct2/show/NCT05007275,Not yet recruiting,0,0,0,0,0,no,NA
GSK,CoV-2 SAM LNP,Phase I,GSK CoV-2 SAM LNP,RNA,10,18–50,2,No,"Open-label, dose-ranging",USA,15/02/2021,04/06/2021,NCT04758962,https://clinicaltrials.gov/ct2/show/NCT04758962,"Active, not recruiting",0,0,0,0,0,no,NA
Clover Biopharmaceuticals Inc/GSK/Dynavax,SCB-2020S,Phase II,Clover SCB-2020S,Protein subunit,0,≥18,2,Yes,"Observer-blind, dose-ranging",Pending,01/08/2021,30/04/2021,NCT04950751,https://clinicaltrials.gov/ct2/show/NCT04950751,Withdrawn,0,0,0,1,0,no,NA
CureVac,CVnCoV,Phase III,CureVac CVnCoV,RNA,0,≥60,2,Yes,Observer-blind,"Argentina, Colombia, Peru",01/10/2021,30/11/2021,NCT04848467,https://clinicaltrials.gov/ct2/show/NCT04848467,Withdrawn,0,0,0,0,0,no,NA
CureVac,CVnCoV,Phase III,CureVac CVnCoV,RNA,0,≥18,2,No,Open-label,Pending,01/10/2021,31/01/2022,NCT04838847,https://clinicaltrials.gov/ct2/show/NCT04838847,Withdrawn,0,0,0,0,0,no,NA
Moderna/NIAID,mRNA-1273,Phase IV,Moderna mRNA-1273,RNA,0,Any,2,Yes,Cluster randomised,Canada,15/04/2021,30/09/2021,NCT04818736,https://clinicaltrials.gov/ct2/show/NCT04818736,Withdrawn,0,0,0,0,0,no,NA
Sanofi Pasteur/GSK,CoV2 preS dTM,Not specified,Sanofi/GSK CoV2 preS dTM,Protein subunit,0,≥18,2,Yes,Observer-blind,Kenya,01/12/2020,30/04/2022,PACTR202011523101903,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=13475,Withdrawn,0,0,0,0,0,no,NA
University of Oxford/AstraZeneca,ChAdOx1-S,Phase III,Oxford ChAdOx1-S,Vector (non-replicating),0,≥18,2,No,Open-label,Russia,02/09/2020,04/12/2020,NCT04540393,https://clinicaltrials.gov/ct2/show/NCT04540393,Withdrawn,0,0,0,0,0,no,NA
University of Queensland/CSL/Seqirus,Sclamp,Phase II/III,Queensland Sclamp,Protein subunit,0,≥18,2,Yes,Observer-blind,Not applicable,15/12/2020,15/12/2020,NCT04806529,https://clinicaltrials.gov/ct2/show/NCT04806529,Withdrawn,0,0,0,0,0,no,NA
"West China Hospital,/Sichuan University",Protein subunit vaccine,Phase II,West China Hospital protein subunit vaccine,Protein subunit,0,18–85,3,Yes,Double-blind,China,01/02/2021,15/05/2021,NCT04718467,https://clinicaltrials.gov/ct2/show/NCT04718467,Withdrawn,0,0,0,0,0,no,NA